2024
Standing, J. F., Buggiotti, L., Guerra-Assuncao, J. A., Woodall, M., Ellis, S., Agyeman, A. A., . . . PANORAMIC Virology Group. (2024). Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients.. Nature communications, 15(1), 1652. doi:10.1038/s41467-024-45641-0DOI: 10.1038/s41467-024-45641-0
2023
Roper, K. J., Thomas, J., Albalawi, W., Maddocks, E., Dobson, S., Alshehri, A., . . . Pollakis, G. (2023). Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera.. Scientific reports, 13(1), 15014. doi:10.1038/s41598-023-41928-2DOI: 10.1038/s41598-023-41928-2
Challenger, E., Penchala, S. D., Hale, C., Fitzgerald, R., Walker, L., Reynolds, H., . . . Else, L. (2023). Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 233. doi:10.1016/j.jpba.2023.115436DOI: 10.1016/j.jpba.2023.115436
A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin (Journal article)
Rametse, C. L., Webb, E., Herrera, C., Alinde, B., Besethi, A., Motaung, B., . . . CHAPS, C. (2023). A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin. AIDS, 37(11), 1651-1659. doi:10.1097/QAD.0000000000003619DOI: 10.1097/QAD.0000000000003619
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease (Journal article)
Gbinigie, O., Ogburn, E., Allen, J., Dorward, J., Dobson, M., Madden, T. -A., . . . Butler, C. C. (2023). Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease. BMJ OPEN, 13(8). doi:10.1136/bmjopen-2022-069176DOI: 10.1136/bmjopen-2022-069176
Herrera, C., Serwanga, J., Else, L., Limakatso, L., Opoka, D., Ssemata, A. S., . . . CHAPS. (2023). Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial. EBIOMEDICINE, 93. doi:10.1016/j.ebiom.2023.104648DOI: 10.1016/j.ebiom.2023.104648
Thompson, B., Dilly-Penchala, S., Amara, A., Reynolds, H., Khoo, S., & Else, L. (2023). Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS. BIOANALYSIS, 15(13), 739-756. doi:10.4155/bio-2023-0057DOI: 10.4155/bio-2023-0057
Granana-Castillo, S., Williams, A., Pham, T., Khoo, S., Hodge, D., Akpan, A., . . . Siccardi, M. (2023). General Framework to Quantitatively Predict Pharmacokinetic Induction Drug-Drug Interactions Using In Vitro Data. CLINICAL PHARMACOKINETICS, 62(5), 737-748. doi:10.1007/s40262-023-01229-3DOI: 10.1007/s40262-023-01229-3
Heseltine, T., Hughes, E., Mattew, J., Murray, S., Ortega-Martorell, S., Olier, I., . . . Khoo, S. (2023). The association of epicardial adipose tissue volume and density with coronary calcium in HIV-positive and HIV-negative patients. JOURNAL OF INFECTION, 86(4), 376-384. doi:10.1016/j.jinf.2023.02.020DOI: 10.1016/j.jinf.2023.02.020
BUZIBYE, A. L. L. A. N., Wools-Kaloustian, K., Olagunju, A., Twinomuhwezi, E., Yiannoutsos, C., Owen, A., . . . Kiragga, A. (2023). Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.. AIDS Research and Therapy. doi:10.1186/s12981-023-00514-2DOI: 10.1186/s12981-023-00514-2
Maddox, V., Reynolds, C., Amara, A., Else, L., Brailsford, S. R., Khoo, S., & Harvala, H. (2023). Undeclared pre-exposure or post-exposure prophylaxis (PrEP/PEP) use among syphilis-positive blood donors, England, 2020 to 2021.. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 28(11). doi:10.2807/1560-7917.es.2023.28.11.2300135DOI: 10.2807/1560-7917.es.2023.28.11.2300135
Goldswain, H., Dong, X., Penrice-Randal, R., Alruwaili, M., Shawli, G. T., Prince, T., . . . Hiscox, J. A. (2023). The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.. Genome biology, 24(1), 47. doi:10.1186/s13059-023-02881-5DOI: 10.1186/s13059-023-02881-5
Rhee, S. -Y., Schapiro, J. M. M., Saladini, F., Zazzi, M., Khoo, S., & Shafer, R. W. W. (2023). Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance. AIDS RESEARCH AND THERAPY, 20(1). doi:10.1186/s12981-023-00503-5DOI: 10.1186/s12981-023-00503-5
Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature (Journal article)
Hodge, D., Hodel, E. M., Hughes, E., Hazenberg, P., Granana Castillo, S., Gibbons, S., . . . Khoo, S. (2023). Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 92(2), 97-105. doi:10.1097/QAI.0000000000003122DOI: 10.1097/QAI.0000000000003122
Butler, C. C., Hobbs, F. D. R., Gbinigie, O. A., Rahman, N. M., Hayward, G., Richards, D. B., . . . Little, P. (2023). Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. LANCET, 401(10373), 281-293. doi:10.1016/S0140-6736(22)02597-1DOI: 10.1016/S0140-6736(22)02597-1
Liew, F., Talwar, S., Cross, A., Willett, B. J., Scott, S., Logan, N., . . . Openshaw, P. J. M. (2023). SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBIOMEDICINE, 87. doi:10.1016/j.ebiom.2022.104402DOI: 10.1016/j.ebiom.2022.104402
2022
Heseltine, T., Hughes, E., Mathew, J., Murray, S., & Khoo, S. (2022). The effect of changing to Bictegravir on lipids using real world data: A brief report. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 47(12), 2182-2187. doi:10.1111/jcpt.13789DOI: 10.1111/jcpt.13789
Granana-Castillo, S., Montanha, M. C., Bearon, R., Khoo, S., & Siccardi, M. (2022). Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling. FRONTIERS IN PHARMACOLOGY, 13. doi:10.3389/fphar.2022.1076266DOI: 10.3389/fphar.2022.1076266
Waters, L., Winston, A., Reeves, I., Boffito, M., Churchill, D., Cromarty, B., . . . Walsh, J. (2022). BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022. HIV MEDICINE, 23, 3-115. doi:10.1111/hiv.13446DOI: 10.1111/hiv.13446
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. CLINICAL PHARMACOLOGY & THERAPEUTICS, 112(6), 1191-1200. doi:10.1002/cpt.2646DOI: 10.1002/cpt.2646
Donovan-Banfield, I., Penrice-Randal, R., Goldswain, H., Rzeszutek, A. M., Pilgrim, J., Bullock, K., . . . Fletcher, T. (2022). Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. NATURE COMMUNICATIONS, 13(1). doi:10.1038/s41467-022-34839-9DOI: 10.1038/s41467-022-34839-9
Petkov, S., Herrera, C., Else, L., Lebina, L., Opoka, D., Seiphetlo, T. B., . . . Chiodi, F. (2022). Short-term oral pre-exposure prophylaxis against HIV-1 modulates the transcriptome of foreskin tissue in young men in Africa. FRONTIERS IN IMMUNOLOGY, 13. doi:10.3389/fimmu.2022.1009978DOI: 10.3389/fimmu.2022.1009978
Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials (Journal article)
Venter, F., Sokhela, S., Calmy, A., Siedner, M. J., Khoo, S., Clayden, P., . . . Collins, S. (2022). Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials. AIDS, 36(13), 1900-1901. doi:10.1097/QAD.0000000000003310DOI: 10.1097/QAD.0000000000003310
Baruch, J., Rojek, A., Kartsonaki, C., Vijayaraghavan, B. K. T., Gonçalves, B. P., Pritchard, M. G., . . . ISARIC Clinical Characterisation Group. (2022). Symptom-based case definitions for COVID-19: Time and geographical variations for detection at hospital admission among 260,000 patients.. Influenza and other respiratory viruses, 16(6), 1040-1050. doi:10.1111/irv.13039DOI: 10.1111/irv.13039
McCallum, A. D., Pertinez, H. E., Chirambo, A. P., Sheha, I., Chasweka, M., Malamba, R., . . . Mwandumba, H. C. (2022). High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis. CLINICAL INFECTIOUS DISEASES, 75(9), 1520-1528. doi:10.1093/cid/ciac228DOI: 10.1093/cid/ciac228
Khoo, S. H., FitzGerald, R., Saunders, G., Middleton, C., Ahmad, S., Edwards, C. J., . . . Vyas, A. (2022). Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Infectious Diseases. doi:10.1016/s1473-3099(22)00644-2DOI: 10.1016/s1473-3099(22)00644-2
Vink, E., Davis, C., MacLean, A., Pascall, D., McDonald, S. E., Gunson, R., . . . Ho, A. (2022). Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study. OPEN FORUM INFECTIOUS DISEASES, 9(11). doi:10.1093/ofid/ofac531DOI: 10.1093/ofid/ofac531
Butler, C., Hobbs, R., Gbinigie, O., Rahman, N. M., Hayward, G., Richards, D., . . . Little, P. (2022). Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial.
Solanke, T., Kamau, F., Esterhuizen, T., Maartens, G., Khoo, S., Joska, J. A., . . . Decloedt, E. H. (2022). Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional Study. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 91(1), 101-108. doi:10.1097/QAI.0000000000003025DOI: 10.1097/QAI.0000000000003025
Keeling, M. J., Dyson, L., Guyver-Fletcher, G., Holmes, A., Semple, M. G., Tildesley, M. J., & Hill, E. M. (2022). Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number. STATISTICAL METHODS IN MEDICAL RESEARCH, 31(9), 1716-1737. doi:10.1177/09622802211070257DOI: 10.1177/09622802211070257
Malaba, T. R., Nakatudde, I., Kintu, K., Colbers, A., Chen, T., Reynolds, H., . . . Khoo, S. (2022). 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. LANCET HIV, 9(8), E534-E543. doi:10.1016/S2352-3018(22)00173-4DOI: 10.1016/S2352-3018(22)00173-4
Adler, H., Gould, S., Hine, P., Snell, L. B., Wong, W., Houlihan, C. F., . . . Price, N. M. (2022). Clinical features and management of human monkeypox: a retrospective observational study in the UK. LANCET INFECTIOUS DISEASES, 22(8), 1153-1162. doi:10.1016/S1473-3099(22)00228-6DOI: 10.1016/S1473-3099(22)00228-6
Garcia-Gallo, E., Merson, L., Kennon, K., Kelly, S., Citarella, B. W., Fryer, D. V., . . . Reyes, L. F. (2022). ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19. SCIENTIFIC DATA, 9(1). doi:10.1038/s41597-022-01534-9DOI: 10.1038/s41597-022-01534-9
Petkov, S., Herrera, C., Else, L., Mugaba, S., Namubiru, P., Odoch, G., . . . Chiodi, F. (2022). Mobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in Africa. FRONTIERS IN IMMUNOLOGY, 13. doi:10.3389/fimmu.2022.965214DOI: 10.3389/fimmu.2022.965214
Alhassan, Y., Twimukye, A., Malaba, T., Myer, L., Waitt, C., Lamorde, M., . . . Taegtmeyer, M. (2022). 'I fear my partner will abandon me': the intersection of late initiation of antenatal care in pregnancy and poor ART adherence among women living with HIV in South Africa and Uganda. BMC PREGNANCY AND CHILDBIRTH, 22(1). doi:10.1186/s12884-022-04896-5DOI: 10.1186/s12884-022-04896-5
Nwogu, J. N., Ngene, S. O., Babalola, C. P., Olagunju, A., Owen, A., Khoo, S. H., . . . Taiwo, B. (2022). Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria. AIDS RESEARCH AND THERAPY, 19(1). doi:10.1186/s12981-022-00462-3DOI: 10.1186/s12981-022-00462-3
Approaches to accelerating the study of new antiretrovirals in pregnancy (Journal article)
Abrams, E. J., Calmy, A., Fairlie, L., Mahaka, I. C., Chimula, L., Flynn, P. M., . . . Siberry, G. K. (2022). Approaches to accelerating the study of new antiretrovirals in pregnancy. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 25. doi:10.1002/jia2.25916DOI: 10.1002/jia2.25916
Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy (Journal article)
Brummel, S. S., Stringer, J., Mills, E., Tierney, C., Caniglia, E. C., Colbers, A., . . . Lockman, S. (2022). Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 25. doi:10.1002/jia2.25917DOI: 10.1002/jia2.25917
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020) (Journal article)
Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2022). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 2050. doi:10.1093/jac/dkac111DOI: 10.1093/jac/dkac111
Alhassan, Y., Twimukye, A., Malaba, T., Myer, L., Waitt, C., Lamorde, M., . . . Taegtmeyer, M. (2022). <i>"It's only fatness, it doesn't kill"</i>: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda. BMC WOMENS HEALTH, 22(1). doi:10.1186/s12905-022-01814-xDOI: 10.1186/s12905-022-01814-x
Else, L., Penchala, S. D., Pillay, A. -D., Seiphetlo, T. B., Lebina, L., Callebaut, C., . . . Herrera, C. (2022). Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue. PHARMACEUTICS, 14(6). doi:10.3390/pharmaceutics14061285DOI: 10.3390/pharmaceutics14061285
Ochanda, P. N., Lamorde, M., Kintu, K., Wang, D., Chen, T., Malaba, T., . . . Khoo, S. (2022). A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy. AIDS RESEARCH AND THERAPY, 19(1). doi:10.1186/s12981-022-00446-3DOI: 10.1186/s12981-022-00446-3
Neumann, J. T., Thao, L. T. P., Murray, A. M., Callander, E., Carr, P. R., Nelson, M. R., . . . ASPREE investigators. (2022). Prediction of disability-free survival in healthy older people.. GeroScience, 44(3), 1641-1655. doi:10.1007/s11357-022-00547-xDOI: 10.1007/s11357-022-00547-x
Total and Unbound Doravirine Concentrations and Viral Suppression in CSF (Journal article)
Tiraboschi, J., Scevola, S., Penchala, S. D., Challenger, E., Else, L., Prieto, P., . . . Podzamczer, D. (2022). Total and Unbound Doravirine Concentrations and Viral Suppression in CSF. CLINICAL INFECTIOUS DISEASES, 74(10), 1855-1858. doi:10.1093/cid/ciab835DOI: 10.1093/cid/ciab835
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions (Journal article)
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. ANNALS OF INTERNAL MEDICINE, 175(5), 744-+. doi:10.7326/M22-0281DOI: 10.7326/M22-0281
Molto, J., Graterol, F., Curran, A., Ramos, N., Imaz, A., Sandoval, D., . . . Paredes, R. (2022). Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 1989-1991. doi:10.1093/jac/dkac126DOI: 10.1093/jac/dkac126
Narhi, F., Moonesinghe, S. R., Shenkin, S. D., Drake, T. M., Mulholland, R. H., Donegan, C., . . . Docherty, A. B. (2022). Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. LANCET DIGITAL HEALTH, 4(4). Retrieved from https://www.webofscience.com/
FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., . . . Khoo, S. (2022). Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES. doi:10.1093/cid/ciac199DOI: 10.1093/cid/ciac199
Walker, L. E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., . . . Fletcher, T. E. (2022). An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. CLINICAL PHARMACOLOGY & THERAPEUTICS, 111(3), 585-594. doi:10.1002/cpt.2463DOI: 10.1002/cpt.2463
Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection (Journal article)
Marzolini, C., Gibbons, S., van Oosterhout, J. J., & Khoo, S. (2022). Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection. CLINICAL PHARMACOKINETICS, 61(3), 339-346. doi:10.1007/s40262-021-01098-8DOI: 10.1007/s40262-021-01098-8
Harvala, H., Reynolds, C., Ijaz, S., Maddox, V., Penchala, S. D., Amara, A., . . . Khoo, S. (2022). Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. SEXUALLY TRANSMITTED INFECTIONS, 98(2), 132-135. doi:10.1136/sextrans-2021-054981DOI: 10.1136/sextrans-2021-054981
Marzolini, C., Marra, F., Boyle, A., Khoo, S., & Back, D. J. (2022). Fluvoxamine for the treatment of COVID-19. LANCET GLOBAL HEALTH, 10(3), E331. Retrieved from https://www.webofscience.com/
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., . . . Screaton, G. R. (2022). SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. Cell, 185(3), 467-484.e15. doi:10.1016/j.cell.2021.12.046DOI: 10.1016/j.cell.2021.12.046
Montanha, M. C., Cottura, N., Booth, M., Hodge, D., Bunglawala, F., Kinvig, H., . . . Siccardi, M. (2022). PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease. FRONTIERS IN PHARMACOLOGY, 13. doi:10.3389/fphar.2022.814134DOI: 10.3389/fphar.2022.814134
Kelly, C., Gurung, R., Kamng'ona, R., Sheha, I., Chammudzi, M., Jambo, K., . . . Klein, N. (2022). Circulating microparticles are increased amongst people presenting with HIV and advanced immune suppression in Malawi and correlate closely with arterial stiffness: a nested case control study. doi:10.12688/wellcomeopenres.17044.2DOI: 10.12688/wellcomeopenres.17044.2
Stockdale, A., & Khoo, S. (2022). Doravirine: its role in HIV treatment. Current Opinion in HIV and AIDS.
Knight, S. R., Gupta, R. K., Ho, A., Pius, R., Buchan, I., Carson, G., . . . Harrison, E. M. (2022). Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. THORAX, 77(6), 606-615. doi:10.1136/thoraxjnl-2021-217629DOI: 10.1136/thoraxjnl-2021-217629
Abouyannis, M., FitzGerald, R., Ngama, M., Mwangudzah, H., Nyambura, Y. K., Ngome, S., . . . Hamaluba, M. (2022). TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults).. Wellcome open research, 7, 90. doi:10.12688/wellcomeopenres.17682.1DOI: 10.12688/wellcomeopenres.17682.1
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry (Preprint)
DOI: 10.12688/wellcomeopenres.17202.3
Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (2021). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.. Wellcome open research, 6, 246. doi:10.12688/wellcomeopenres.17202.2DOI: 10.12688/wellcomeopenres.17202.2
2021
Heseltine, T. D., Murray, S. W., Khoo, S., & Ruzsics, B. (2021). Cardiovascular computed tomography and HIV: The evolving role of imaging biomarkers in enhanced risk prediction. IMAGING, 13(2), 106-118. doi:10.1556/1647.2021.00025DOI: 10.1556/1647.2021.00025
Niemi, M. E. K., Karjalainen, J., Daly, M., Ganna, A., Mehtonen, J., Cordioli, M., . . . Dopazo, X. (2021). Mapping the human genetic architecture of COVID-19. NATURE, 600(7889), 472-+. doi:10.1038/s41586-021-03767-xDOI: 10.1038/s41586-021-03767-x
Sinxadi, P. Z., Khoo, S. H., & Boffito, M. (2021). Pharmacokinetic interactions of modern antiretroviral therapy. AIDS, 35, S145-S151. doi:10.1097/QAD.0000000000002950DOI: 10.1097/QAD.0000000000002950
Venter, W. D. F., Sokhela, S., Calmy, A., Mkhondwane, L., Bosch, B., Chandiwana, N., . . . Collins, S. (2021). Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS, 35, S183-S188. doi:10.1097/QAD.0000000000003092DOI: 10.1097/QAD.0000000000003092
The value of open-source clinical science in pandemic response: lessons from ISARIC (Journal article)
The value of open-source clinical science in pandemic response: lessons from ISARIC (2021). LANCET INFECTIOUS DISEASES, 21(12), 1623-1624. doi:10.1016/S1473-3099(21)00565-XDOI: 10.1016/S1473-3099(21)00565-X
Amara, A., Penchala, S. D., Else, L., Hale, C., FitzGerald, R., Walker, L., . . . Khoo, S. (2021). The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 206. doi:10.1016/j.jpba.2021.114356DOI: 10.1016/j.jpba.2021.114356
Antiviral activity of Molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and implications for the therapeutic window and resistance (Preprint)
DOI: 10.1101/2021.11.23.469695
de, S. T. I., Liu, G., Lindsey, B. B., Dong, D., Moore, S. C., Hsu, N. S., . . . Dong, T. (2021). The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. ISCIENCE, 24(11). doi:10.1016/j.isci.2021.103353DOI: 10.1016/j.isci.2021.103353
Khoo, S. H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., . . . Griffiths, G. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3286-3295. doi:10.1093/jac/dkab318DOI: 10.1093/jac/dkab318
Wickenhagen, A., Sugrue, E., Lytras, S., Kuchi, S., Noerenberg, M., Turnbull, M. L., . . . Wilson, S. J. (2021). A prenylated dsRNA sensor protects against severe COVID-19. SCIENCE, 374(6567). doi:10.1126/science.abj3624DOI: 10.1126/science.abj3624
Ikumi, N. M., Pillay, K., Tilburgs, T., Malaba, T. R., Dzanibe, S., Enninga, E. A. L., . . . Gray, C. M. (2021). T-Cell Homeostatic Imbalance in Placentas From Women With Human Immunodeficiency Virus in the Absence of Vertical Transmission. JOURNAL OF INFECTIOUS DISEASES, 224, S670-S682. doi:10.1093/infdis/jiab192DOI: 10.1093/infdis/jiab192
Justice, A. C., Gordon, K. S., Romero, J., Edelman, E. J., Garcia, B. J., Jones, P., . . . Jacobson, D. (2021). Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study. LANCET HEALTHY LONGEVITY, 2(10), E639-E650. Retrieved from https://www.webofscience.com/
Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (n.d.). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. Wellcome Open Research, 6, 246. doi:10.12688/wellcomeopenres.17202.1DOI: 10.12688/wellcomeopenres.17202.1
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2 (Preprint)
DOI: 10.1101/2021.09.10.21263376
Heseltine, T., Murray, S., Ortega-Martorell, S., Olier, I., Lip, G. Y. H., & Khoo, S. (2021). Associations of Hepatosteatosis With Cardiovascular Disease in HIV-Positive and HIV-Negative Patients: The Liverpool HIV-Heart Project. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 87(5), 1221-1227. doi:10.1097/QAI.0000000000002721DOI: 10.1097/QAI.0000000000002721
Hiscox, J. A., Khoo, S. H., Stewart, J. P., & Owen, A. (2021). Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(9), 2230-2233. doi:10.1093/jac/dkab189DOI: 10.1093/jac/dkab189
Russell, C. D., Fairfield, C. J., Drake, T. M., Turtle, L., Seaton, R. A., Wootton, D. G., . . . Ho, A. (2021). Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. LANCET MICROBE, 2(8), E354-E365. doi:10.1016/S2666-5247(21)00090-2DOI: 10.1016/S2666-5247(21)00090-2
Kelly, C., Tinago, W., Alber, D., Hunter, P., Luckhurst, N., Connolly, J., . . . Khoo, S. (n.d.). Inflammatory pathways amongst people living with HIV in Malawi differ according to socioeconomic status. PLOS ONE, 16(8), e0256576. doi:10.1371/journal.pone.0256576DOI: 10.1371/journal.pone.0256576
Griffiths, G. O., FitzGerald, R., Jaki, T., Corkhill, A., Reynolds, H., Ewings, S., . . . Khoo, S. (2021). AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. TRIALS, 22(1). doi:10.1186/s13063-021-05458-4DOI: 10.1186/s13063-021-05458-4
Drake, T. M., Riad, A. M., Fairfield, C. J., Egan, C., Knight, S. R., Pius, R., . . . Semple, M. G. (2021). Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. LANCET, 398(10296), 223-237. Retrieved from https://www.webofscience.com/
Pertinez, H., Rajoli, R. K. R., Khoo, S. H., & Owen, A. (2021). Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2121-2128. doi:10.1093/jac/dkab135DOI: 10.1093/jac/dkab135
Herrera, C., Lwanga, J., Lee, M., Mantori, S., Amara, A., Else, L., . . . Fox, J. (2021). Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2129-2136. doi:10.1093/jac/dkab136DOI: 10.1093/jac/dkab136
De Francesco, D., Wang, X., Dickinson, L., Underwood, J., Bagkeris, E., Babalis, D. S., . . . Boffito, M. (2021). Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV. PLOS ONE, 16(7). doi:10.1371/journal.pone.0253861DOI: 10.1371/journal.pone.0253861
Docherty, A., Mulholland, R., Lone, N. I., Cheyne, C., De Angelis, D., Diaz-Ordaz, K., . . . Semple, M. (2021). Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 773-785. doi:10.1016/S2213-2600(21)00175-2DOI: 10.1016/S2213-2600(21)00175-2
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. (Journal article)
Drake, T. M., Fairfield, C. J., Pius, R., Knight, S. R., Norman, L., Girvan, M., . . . ISARIC4C Investigators. (2021). Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.. The Lancet. Rheumatology, 3(7), e498-e506. doi:10.1016/s2665-9913(21)00104-1DOI: 10.1016/s2665-9913(21)00104-1
Yates, T., Zaccardi, F., Islam, N., Razieh, C., Gillies, C. L., Lawson, C. A., . . . Khunti, K. (2021). Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. OBESITY, 29(7), 1223-1230. doi:10.1002/oby.23178DOI: 10.1002/oby.23178
Hodge, D., Back, D. J., Gibbons, S., Khoo, S. H., & Marzolini, C. (2021). Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. CLINICAL PHARMACOKINETICS, 60(7), 835-853. doi:10.1007/s40262-021-01005-1DOI: 10.1007/s40262-021-01005-1
Bloom, C. I., Drake, T. M., Docherty, A. B., Lipworth, B. J., Johnston, S. L., Nguyen-Van-Tam, J. S., . . . Openshaw, P. J. M. (2021). Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 699-711. doi:10.1016/S2213-2600(21)00013-8DOI: 10.1016/S2213-2600(21)00013-8
Nwogu, J. N., Gandhi, M., Owen, A., Khoo, S., Taiwo, B., Olagunju, A., . . . Babalola, C. P. (2021). Associations between efavirenz concentrations, pharmacogenetics, and neurocognitive performance in people living with HIV in Nigeria.. AIDS (London, England). doi:10.1097/qad.0000000000002984DOI: 10.1097/qad.0000000000002984
Leclerc, Q. J., Fuller, N. M., Keogh, R. H., Diaz-Ordaz, K., Sekula, R., Semple, M. G., . . . Knight, G. M. (2021). Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. BMC HEALTH SERVICES RESEARCH, 21(1). doi:10.1186/s12913-021-06509-xDOI: 10.1186/s12913-021-06509-x
Available Agents: Contraindications and Potential Drug–Drug Interactions (Chapter)
Khoo, S., Marra, F., & Boyle, A. (2021). Available Agents: Contraindications and Potential Drug–Drug Interactions. In Hepatitis C: Care and Treatment (pp. 43-74). Springer International Publishing. doi:10.1007/978-3-030-67762-6_4DOI: 10.1007/978-3-030-67762-6_4
Heal, J. R., Sheridan, J. M., Kulkarni, M., Liptrott, N., Egan, D., Khoo, S., . . . Hamilton, W. D. O. (2021). AUTOSTERE: Systematic Search for Scaffold Replacement Opportunities within Structural Databases. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 61(4), 1778-1788. doi:10.1021/acs.jcim.0c01261DOI: 10.1021/acs.jcim.0c01261
Pairo-Castineira, E., Clohisey, S., Klaric, L., Bretherick, A. D., Rawlik, K., Pasko, D., . . . Baillie, J. K. (2021). Genetic mechanisms of critical illness in COVID-19. NATURE, 591(7848), 92-+. doi:10.1038/s41586-020-03065-yDOI: 10.1038/s41586-020-03065-y
Mora-Peris, B., Keegan, M. R., Penchala, S. D., Vera, J. H., Underwood, J., Khan, M., . . . Winston, A. (2021). Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial. HIV RESEARCH & CLINICAL PRACTICE, 22(6), 151-159. doi:10.1080/25787489.2021.1997880DOI: 10.1080/25787489.2021.1997880
Pharmacokinetic and pharmacodynamic study of tenofovir and tenofovir alafenamide for PrEP in foreskin tissue (Conference Paper)
Herrera, C., Else, L., Penchala, S. D., Pillay, A. -D. A., Seiphetlo, T. B., Lebina, L., . . . Khoo, S. (2021). Pharmacokinetic and pharmacodynamic study of tenofovir and tenofovir alafenamide for PrEP in foreskin tissue. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 24. Retrieved from https://www.webofscience.com/
2020
Thompson, C. P., Grayson, N. E., Paton, R. S., Bolton, J. S., Lourenco, J., Penman, B. S., . . . Simmonds, P. (2020). Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. EUROSURVEILLANCE, 25(42), 33-41. doi:10.2807/1560-7917.ES.2020.25.42.2000685DOI: 10.2807/1560-7917.ES.2020.25.42.2000685
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect (Journal article)
Stader, F., Khoo, S., Stoeckle, M., Back, D., Hirsch, H. H., Battegay, M., & Marzolini, C. (2020). Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(10), 3084-3086. doi:10.1093/jac/dkaa253DOI: 10.1093/jac/dkaa253
Deutschmann, E., Bucher, H. C., Jaeckel, S., Gibbons, S., McAllister, K., Scherrer, A., . . . Study, S. H. I. V. C. (2020). Prevalence of potential drug-drug interactions in patients of the Swiss HIV cohort study in the era of HIV integrase inhibitors. Clinical Infectious Diseases, 20, 40. doi:10.1093/cid/ciaa918DOI: 10.1093/cid/ciaa918
Okoli, C., Schwenk, A., Radford, M., Myland, M., Taylor, S., Darley, A., . . . Khoo, S. (n.d.). Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database. HIV Medicine. doi:10.1111/hiv.12879DOI: 10.1111/hiv.12879
Lopez-Centeno, B., Badenes-Olmedo, C., Mataix-Sanjuan, A., Bellon, J. M., Perez-Latorre, L., Lopez, J. C., . . . Berenguer, J. (2020). Potentially inappropriate medications in older adults living with HIV. HIV MEDICINE, 21(8), 541-546. doi:10.1111/hiv.12883DOI: 10.1111/hiv.12883
Lopez-Centeno, B., Badenes-Olmedo, C., Mataix-Sanjuan, A., McAllister, K., Bellon, J. M., Gibbons, S., . . . Berenguer, J. (2020). Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study. In CLINICAL INFECTIOUS DISEASES Vol. 71 (pp. 353-362). doi:10.1093/cid/ciz811DOI: 10.1093/cid/ciz811
AlAkhras, A., AlMessabi, A. H., Abuzeid, H., Khoo, S., & Nsutebu, E. F. (2020). Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?. POSTGRADUATE MEDICAL JOURNAL, 96(1137), 377-378. doi:10.1136/postgradmedj-2020-137990DOI: 10.1136/postgradmedj-2020-137990
Pushpakom, S. P., Kolamunnage-Dona, R., Taylor, C., Foster, T., Spowart, C., Garcia-Finana, M., . . . Pirmohamed, M. (n.d.). TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clinical Infectious Diseases. doi:10.1093/cid/ciz589DOI: 10.1093/cid/ciz589
Kintu, K., Malaba, T., Nakibuka, J., Papamichael, C., Colbers, A., Byrne, K., . . . Khoo, S. (2020). Dolutegravir versus efavirenz when starting HIV therapy in late pregnancy: a randomised controlled trial. The Lancet HIV, 7(5), e332-e339. doi:10.1016/s2352-3018(20)30050-3DOI: 10.1016/s2352-3018(20)30050-3
Elliot, E. R., Neary, M., Else, L., Khoo, S., Moyle, G., Carr, D. F., . . . Owen, A. (2020). Genetic influence of <i>ABCG2, UGT1A1</i> and <i>NR1I2</i> on dolutegravir plasma pharmacokinetics. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1259-1266. doi:10.1093/jac/dkz558DOI: 10.1093/jac/dkz558
Francis, J., Barnes, K. I., Workman, L., Kredo, T., Vestergaard, L. S., Hoglund, R. M., . . . Denti, P. (2020). An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(5). doi:10.1128/AAC.02394-19DOI: 10.1128/AAC.02394-19
Tiraboschi, J., Imaz, A., Khoo, S., Niubo, J., Prieto, P., Saumoy, M., . . . Podzamczer, D. (2020). Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56). JOURNAL OF INFECTIOUS DISEASES, 221(9), 1425-1428. doi:10.1093/infdis/jiz624DOI: 10.1093/infdis/jiz624
Abdullahi, S. T., Soyinka, J. O., Olagunju, A., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2020). <i>CYP2B6</i>*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers. JOURNAL OF CLINICAL PHARMACOLOGY, 60(3), 351-360. doi:10.1002/jcph.1527DOI: 10.1002/jcph.1527
Abdullahi, S. T., Soyinka, J. O., Olagunju, A., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2020). Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by <i>CYP2B6</i> c.516G>T Genotypes. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(3). doi:10.1128/AAC.00947-19DOI: 10.1128/AAC.00947-19
Anderson, S. G., McCaul, M., Khoo, S., Wiesner, L., Sacktor, N., Joska, J. A., & Decloedt, E. H. (2020). The neurologic phenotype of South African patients with HIV-associated neurocognitive impairment. NEUROLOGY-CLINICAL PRACTICE, 10(1), 15-22. doi:10.1212/CPJ.0000000000000687DOI: 10.1212/CPJ.0000000000000687
Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F. A., . . . POPPY Study. (2020). Plasma NRTI concentration and their associations with liver and renal parameters in people living with HIV.. AIDS. doi:10.1097/QAD.0000000000002479DOI: 10.1097/QAD.0000000000002479
Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial (Journal article)
Arenas-Pinto, A., Stohr, W., Khoo, S., Clarke, A., Beeching, N., Warwick, Z., . . . Paton, N. I. (2020). Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial. ANTIVIRAL THERAPY, 25(1), 55-59. doi:10.3851/IMP3340DOI: 10.3851/IMP3340
TB control programmes remain an important gateway to HIV diagnosis in the era of expanded access to HIV care (Journal article)
McCallum, A. D., Sheha, I., Chasweka, M., Banda, G., Davies, G. R., Khoo, S. H., . . . Sloan, D. J. (2020). TB control programmes remain an important gateway to HIV diagnosis in the era of expanded access to HIV care. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 24(1), 131-132. doi:10.5588/ijtld.19.0504DOI: 10.5588/ijtld.19.0504
The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid (Journal article)
Penchala, S. D., Alagaratnam, J., Challenger, E., Amara, A., Else, L., Winston, A., & Khoo, S. (2020). The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid. BIOMEDICAL CHROMATOGRAPHY, 34(1). doi:10.1002/bmc.4711DOI: 10.1002/bmc.4711
2019
Boyle, A., Moss, C. E., Marzolini, C., & Khoo, S. (2019). Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine. CLINICAL PHARMACOKINETICS, 58(12), 1553-1565. doi:10.1007/s40262-019-00806-9DOI: 10.1007/s40262-019-00806-9
Feiterna-Sperling, C., Krüger, R., Amara, A., Khoo, S., & Waitt, C. (2019). Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman.. AIDS (London, England), 33(15), 2443-2444. doi:10.1097/qad.0000000000002360DOI: 10.1097/qad.0000000000002360
Fairlie, L., Waitt, C., Lockman, S., Moorehouse, M., Abrams, E., Clayden, P., . . . Cherisch, M. (2019). Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?. Journal of the International AIDS Society. doi:10.1002/jia2.25372DOI: 10.1002/jia2.25372
Feiterna-Sperling, C., Krueger, R., Amara, A., Khoo, S., & Waitt, C. (2019). Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman. AIDS, 33(15), 2443-2444. doi:10.1097/QAD.0000000000002360DOI: 10.1097/QAD.0000000000002360
Cranston, R. D., Dezzutti, C. S., Siegel, A., Engstrom, J., Shetler, C., Richardson-Harman, N., . . . McGowan, I. (2019). A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. AIDS RESEARCH AND HUMAN RETROVIRUSES, 35(9), 794-804. doi:10.1089/aid.2018.0265DOI: 10.1089/aid.2018.0265
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list (Journal article)
Penazzato, M., Townsend, C. L., Rakhmanina, N., Cheng, Y., Archary, M., Cressey, T. R., . . . Townsend, C. (2019). Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. LANCET HIV, 6(9), E623-E631. doi:10.1016/S2352-3018(19)30193-6DOI: 10.1016/S2352-3018(19)30193-6
Elliot, E. R., Bisdomini, E., Penchala, S. D., Khoo, S., Nwokolo, N., & Boffito, M. (2019). Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat.. HIV research & clinical practice, 1-10. doi:10.1080/25787489.2019.1638077DOI: 10.1080/25787489.2019.1638077
Mofenson, L. M., Pozniak, A. L., Wambui, J., Raizes, E., Ciaranello, A., Clayden, P., . . . Ford, N. P. (2019). Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 22(7). doi:10.1002/jia2.25352DOI: 10.1002/jia2.25352
Walimbwa, S., Lamorde, M., Waitt, C., Amara, A., & Khoo, S. (2019). Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine". ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(6). doi:10.1128/AAC.00593-19DOI: 10.1128/AAC.00593-19
Banda, C. G., Chaponda, M., Mukaka, M., Mulenga, M., Hachizovu, S., Kabuya, J. B., . . . Mwapasa, V. (2019). Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial. MALARIA JOURNAL, 18. doi:10.1186/s12936-019-2818-7DOI: 10.1186/s12936-019-2818-7
Bracchi, M., van Halsema, C., Post, F., Awosusi, F., Barbour, A., Bradley, S., . . . Pozniak, A. (2019). British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. doi:10.1111/hiv.12748DOI: 10.1111/hiv.12748
Jacobs, T. G., Burger, D. M., Pranger, A. D., Khoo, S. H., Drenth, J. P. H., & van Crevel, R. (2019). Carbamazepine intervention in a patient with efavirenz-induced liver injury. AIDS, 33(6), 1097-1098. doi:10.1097/QAD.0000000000002116DOI: 10.1097/QAD.0000000000002116
Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment (Conference Paper)
Alagaratnam, J., Dilly-Penchala, S., Challenger, E., Else, L., Legg, K., Petersen, C., . . . Winston, A. (2019). Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 85 (pp. 1039-1040). doi:10.1111/bcp.13878DOI: 10.1111/bcp.13878
Elliot, E. R., Cerrone, M., Challenger, E., Else, L., Amara, A., Bisdomini, E., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(5), 1466. doi:10.1093/jac/dky571DOI: 10.1093/jac/dky571
Duwal, S., Seeler, D., Dickinson, L., Khoo, S., & von Kleist, M. (2019). The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis. FRONTIERS IN PHARMACOLOGY, 10. doi:10.3389/fphar2019.00199DOI: 10.3389/fphar2019.00199
Duwal, S., Seeler, D., Dickinson, L., Khoo, S., & von Kleist, M. (2019). The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis.. Frontiers in pharmacology, 10, 199. doi:10.3389/fphar.2019.00199DOI: 10.3389/fphar.2019.00199
Gini, J., Olagunju, A., Dickinson, L., Waitt, C., Neary, M., Else, L. J., . . . Khoo, S. (2019). Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. PHARMACOGENOMICS, 20(4), 217-224. doi:10.2217/pgs-2018-0111DOI: 10.2217/pgs-2018-0111
Walimbwa, S. I., Lamorde, M., Waitt, C., Kaboggoza, J., Else, L., Byakika-Kibwika, P., . . . Khoo, S. H. (2019). Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(2). doi:10.1128/AAC.01310-18DOI: 10.1128/AAC.01310-18
Duwal, S., Dickinson, L., Khoo, S., & von Kleist, M. (2019). Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis.. PLoS computational biology, 15(1), e1006740. doi:10.1371/journal.pcbi.1006740DOI: 10.1371/journal.pcbi.1006740
Kelly, C., Mwandumba, H. C., Heyderman, R. S., Jambo, K., Kamng'ona, R., Chammudzi, M., . . . Khoo, S. (2019). HIV-Related Arterial Stiffness in Malawian Adults Is Associated With the Proportion of PD-1–Expressing CD8+ T Cells and Reverses With Antiretroviral Therapy. The Journal of infectious diseases. doi:10.1093/infdis/jiz015DOI: 10.1093/infdis/jiz015
Abdullahi, S. T., Olagunju, A., Soyinka, J. O., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2019). Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?. British journal of clinical pharmacology. doi:10.1111/bcp.13821DOI: 10.1111/bcp.13821
Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website (Conference Paper)
Gibbons, S., Marzolini, C., Moss, C., McAllister, K., Chiong, J., Back, D., & Khoo, S. (2019). Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website. In HIV MEDICINE Vol. 20 (pp. 44-45). Retrieved from https://www.webofscience.com/
Kelly, C., Tinago, W., Hunter, P., Alber, D., Luckhurst, N., Connolly, J., . . . Klein, N. (2019). Effect of CMV viraemia on endothelial dysfunction over 42 weeks in Malawian adults initiating ART with advanced immune suppression. In HIV MEDICINE Vol. 20 (pp. 140-141). Retrieved from https://www.webofscience.com/
Elliot, E. R., Cerrone, M., Else, L., Amara, A., Bisdomini, E., Khoo, S., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.. The Journal of antimicrobial chemotherapy, 74(1), 149-156. doi:10.1093/jac/dky384DOI: 10.1093/jac/dky384
Lopez-Centeno, B., Badenes-Olmedo, C., Mataix-Sanjuan, A., Bellon-Cano, J. M., Perez-Latorre, L., Lopez, J. C., . . . Berenguer, J. (2019). Potentially inappropriate medications in older adults with HIV in the region of Madrid, Spain. In HIV MEDICINE Vol. 20 (pp. 132). Retrieved from https://www.webofscience.com/
Waitt, C., Orrell, C., Walimbwa, S., Singh, Y., Kintu, K., Simmons, B., . . . Khoo, S. (2019). Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLOS MEDICINE, 16(9). doi:10.1371/journal.pmed.1002895DOI: 10.1371/journal.pmed.1002895
Pushpakom, S., Kolamunnage-Dona, R., Taylor, C., Foster, T., Spowart, C., Garcia-Finana, M., . . . Pirmohamed, M. (2019). Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT.
The role of raltegravir alone or combined with lamivudine as PrEP: a phase 2 randomised controlled clinical trial (Conference Paper)
Fox, J., Herrera, C., Lwanga, J., Lee, M., Else, L., Amara, A., . . . Dickenson, L. (2019). The role of raltegravir alone or combined with lamivudine as PrEP: a phase 2 randomised controlled clinical trial. In HIV MEDICINE Vol. 20 (pp. 5-6). Retrieved from https://www.webofscience.com/
Murtagh, R., Else, L. J., Kuan, K. B. K., Khoo, S. H., Jackson, V., Patel, A., . . . Lambert, J. S. (2019). Therapeutic drug monitoring of darunavir/ritonavir in pregnancy. ANTIVIRAL THERAPY, 24(3), 229-233. doi:10.3851/IMP3291DOI: 10.3851/IMP3291
2018
Decloedt, E. H., Sinxadi, P. Z., van Zyl, G. U., Wiesner, L., Khoo, S., Joska, J. A., . . . Maartens, G. (2018). Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.. The Journal of antimicrobial chemotherapy. doi:10.1093/jac/dky481DOI: 10.1093/jac/dky481
Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk (Journal article)
Gini, J., Penchala, S. D., Amara, A., Challenger, E., Egan, D., Waitt, C., . . . Else, L. J. (2018). Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk. BIOANALYSIS, 10(23), 1933-1945. doi:10.4155/bio-2018-0085DOI: 10.4155/bio-2018-0085
Gini, J., Amara, A., Penchala, S. D., Back, D. J., Else, L., Egan, D., . . . Khoo, S. H. (2018). Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.. International journal of STD & AIDS, 956462418809749. doi:10.1177/0956462418809749DOI: 10.1177/0956462418809749
Seden, K., Kiiza, D., Laker, E., Arinaitwe, W. J., Waitt, C., Lamorde, M., & Khoo, S. (2018). High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(11), 3158-3161. doi:10.1093/jac/dky298DOI: 10.1093/jac/dky298
Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in <i>Plasmodium falciparum</i>-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(11). doi:10.1128/AAC.01162-18DOI: 10.1128/AAC.01162-18
Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches (Conference Paper)
Lankheet, N. A. G., Ferrier, K. R. M., Gibbons, S. E., Burger, D. M., McAllister, K., Martin, J. L. M., . . . Jansman, F. G. (2018). Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches. In ANNALS OF ONCOLOGY Vol. 29. Retrieved from https://www.webofscience.com/
Vaughan, A., Aarons, E., Astbury, J., Balasegaram, S., Beadsworth, M., Beck, C. R., . . . Wilburn, J. (2018). Two cases of monkeypox imported to the United Kingdom, September 2018. EUROSURVEILLANCE, 23(38), 2-6. doi:10.2807/1560-7917.ES.2018.23.38.1800509DOI: 10.2807/1560-7917.ES.2018.23.38.1800509
Danjuma, M. I., Egan, D., Abubeker, I. Y., Post, F., & Khoo, S. (2018). Polymorphisms of tenofovir disoproxil fumarate transporters and risk of kidney tubular dysfunction in HIV-positive patients: genetics of tenofovir transporters. INTERNATIONAL JOURNAL OF STD & AIDS, 29(14), 1384-1389. doi:10.1177/0956462418786562DOI: 10.1177/0956462418786562
Imaz, A., Niubo, J., Amara, A., Khoo, S., Ferrer, E., Tiraboschi, J. M., . . . Podzamczer, D. (2018). Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39). JOURNAL OF NEUROVIROLOGY, 24(4), 391-397. doi:10.1007/s13365-018-0626-4DOI: 10.1007/s13365-018-0626-4
Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(8). doi:10.1128/AAC.00634-18DOI: 10.1128/AAC.00634-18
Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.. Antimicrobial agents and chemotherapy, 62(8), e00634-e00618. doi:10.1128/aac.00634-18DOI: 10.1128/aac.00634-18
Orrell, C., Kintu, K., Coombs, J. A., Amara, A., Myer, L., Kaboggoza, J., . . . Lamorde, M. (2018). DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21 (pp. 166). Retrieved from https://www.webofscience.com/
Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications (Journal article)
Stader, F., Kinvig, H., Battegay, M., Khoo, S., Owen, A., Siccardi, M., & Marzolini, C. (2018). Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00717-18DOI: 10.1128/AAC.00717-18
Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Pharmacokinetics and Safety Profile of Artesunate-Amodiaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00412-18DOI: 10.1128/AAC.00412-18
Drug Interactions Between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine (Journal article)
Walimbwa, S., Lamorde, M., Waitt, C., Kaboggoza, J., Else, L., Byakika-Kibwika, P., . . . Khoo, S. (2018). Drug Interactions Between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. doi:10.1101/351684DOI: 10.1101/351684
Duwal, S., Dickinson, L., Khoo, S., & von Kleist, M. (2018). Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes. PLOS COMPUTATIONAL BIOLOGY, 14(6). doi:10.1371/journal.pcbi.1006155DOI: 10.1371/journal.pcbi.1006155
Development of an online drug-drug interaction resource to support prescribing of oncolytics (Conference Paper)
Lankheet, N. A. G., Jansman, F. G., Gibbons, S. E., Burger, D. M., McAllister, K., Khoo, S. H., & Van Erp, N. P. (2017). Development of an online drug-drug interaction resource to support prescribing of oncolytics. In ANNALS OF ONCOLOGY Vol. 28. Retrieved from https://www.webofscience.com/
Development of an online drug-drug interaction resource to support safe prescription of oncolytics. (Conference Paper)
Van Erp, N. P., Ferrier, K. R. M., Gibbons, S. E., Burger, D., McAllister, K., Martin, J. L. M., . . . Lankheet, N. A. G. (2018). Development of an online drug-drug interaction resource to support safe prescription of oncolytics.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.e18574DOI: 10.1200/JCO.2018.36.15_suppl.e18574
Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals (Journal article)
Mora-Peris, B., Bouliotis, G., Ranjababu, K., Clarke, A., Post, F. A., Nelson, M., . . . Winston, A. (2018). Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals. AIDS, 32(8), 1007-1015. doi:10.1097/QAD.0000000000001786DOI: 10.1097/QAD.0000000000001786
Olagunju, A., Rajoli, R. K. R., Atoyebi, S. A., Khoo, S., Owen, A., & Siccardi, M. (2018). Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. AAS Open Research, 1(16). doi:10.12688/aasopenres.12860.1DOI: 10.12688/aasopenres.12860.1
Marra, F., zu Siederdissen, C. H., Khoo, S., Back, D., Schlag, M., Ouwerkerk-Mahadevan, S., . . . Cornberg, M. (2018). Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84(5), 961-971. doi:10.1111/bcp.13519DOI: 10.1111/bcp.13519
Cirrincione, L. R., Penchala, S. D., Scarsi, K. K., Podany, A. T., Winchester, L. C., Back, D. J., . . . Else, L. J. (2018). Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1084, 106-112. doi:10.1016/j.jchromb.2018.03.023DOI: 10.1016/j.jchromb.2018.03.023
Smolders, E. J., Willemse, S. B., El-Sherif, O., Khoo, S., & Burger, D. M. (2018). The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report.. Annals of hepatology, 17(3), 525-529. doi:10.5604/01.3001.0011.7398DOI: 10.5604/01.3001.0011.7398
Elliot, E., Neary, M. G., Else, L., Khoo, S., Moyle, G., Carr, D., . . . Boffito, M. (n.d.). ABCG2 rs2231142 and NR1I2 rs2472677 influence dolutegravir concentrations in plasma.. In CROI. Boston, MA, USA.
Ruggiero, A., Cozzi-Lepri, A., Beloukas, A., Richman, D., Khoo, S., Phillips, A., & Geretti, A. M. (2018). Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy. OPEN FORUM INFECTIOUS DISEASES, 5(2). doi:10.1093/ofid/ofy032DOI: 10.1093/ofid/ofy032
Waitt, C., Olagunju, A., Nakalema, S., Kyohaire, I., Owen, A., Lamorde, M., & Khoo, S. (2018). Plasma and Breast Milk Pharmacokinetics of Emtricitabine, Tenofovir and Lamivudine Using Dried Blood and Breast Milk Spots in Nursing African Mother-Infant Pairs. Journal of Antimicrobial Chemotherapy, 73(4), 1013-1019. doi:10.1093/jac/dkx507DOI: 10.1093/jac/dkx507
Jackson, A., Else, L., Higgs, C., Karolia, Z., Khoo, S., Back, D., . . . Boffito, M. (2018). Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naive HIV-1-infected individuals. HIV CLINICAL TRIALS, 19(1), 31-37. doi:10.1080/15284336.2017.1408928DOI: 10.1080/15284336.2017.1408928
Development of a drug-drug interaction website to support prescribing of oncolytics (Conference Paper)
Ferrier, K., Jansman, F., Burger, D., McAllister, K., Gibbons, S., Khoo, S., . . . Lankheet, N. (2018). Development of a drug-drug interaction website to support prescribing of oncolytics. In INTERNATIONAL JOURNAL OF CLINICAL PHARMACY Vol. 40 (pp. 735-736). Retrieved from https://www.webofscience.com/
Olagunju, A., Schipani, A., Bolaji, O., Khoo, S., & Owen, A. (2018). Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(1), 165-172. doi:10.1093/jac/dkx334DOI: 10.1093/jac/dkx334
HIV infection and stroke. (Journal article)
Benjamin, L., & Khoo, S. (2018). HIV infection and stroke.. Handbook of clinical neurology, 152, 187-200. doi:10.1016/b978-0-444-63849-6.00015-3DOI: 10.1016/b978-0-444-63849-6.00015-3
Novel Protocol to Compare PrEP Drugs, Dosing and Schedule Using Ex Vivo Challenge on Resected Foreskin Tissue: Protocol for the CHAPS RCT (Conference Paper)
Nash, S., Herrera, C., Serwanga, J., Ruzagira, E., O'Hagan, K., Kelly, C., . . . Fox, J. (2018). Novel Protocol to Compare PrEP Drugs, Dosing and Schedule Using Ex Vivo Challenge on Resected Foreskin Tissue: Protocol for the CHAPS RCT. In AIDS RESEARCH AND HUMAN RETROVIRUSES Vol. 34 (pp. 364). Retrieved from https://www.webofscience.com/
Plasma NRTI concentrations and renal function in people with HIV (Conference Paper)
Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F., . . . Sabin, C. (2018). Plasma NRTI concentrations and renal function in people with HIV. In HIV MEDICINE Vol. 19 (pp. S16-S17). Retrieved from https://www.webofscience.com/
Plasma NRTI exposure and associations with serum alanine aminotransferase in people living with HIV (Conference Paper)
Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F., . . . Sabin, C. (2018). Plasma NRTI exposure and associations with serum alanine aminotransferase in people living with HIV. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21. Retrieved from https://www.webofscience.com/
Using Climate-HIV to describe non-antiretroviral use and potential DDIs for people living with HIV within a UK cohort (Conference Paper)
Okoli, C., Khoo, S., Schwenk, A., Radford, M., Myland, M., Taylor, S., . . . Benn, P. (2018). Using Climate-HIV to describe non-antiretroviral use and potential DDIs for people living with HIV within a UK cohort. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21. Retrieved from https://www.webofscience.com/
2017
Amara, A. B., Else, L. J., Carey, D., Khoo, S., Back, D. J., Amin, J., . . . Puls, R. L. (2017). Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study. THERAPEUTIC DRUG MONITORING, 39(6), 654-658. Retrieved from http://gateway.webofknowledge.com/
Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis - results from the UK Expanded Access programme. (Conference Paper)
El-Sherif, O., Pertinez, H., Irving, W., Penchala, S. D., McLauchlan, J., Foster, G. R., . . . Khoo, S. (2017). Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis - results from the UK Expanded Access programme.. In HEPATOLOGY Vol. 66 (pp. 831A-832A). Retrieved from https://www.webofscience.com/
Belli, L. S., Duvoux, C., Berenguer, M., Berg, T., Coilly, A., Colle, I., . . . Strazzabosco, M. (2017). ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. JOURNAL OF HEPATOLOGY, 67(3), 585-602. doi:10.1016/j.jhep.2017.03.006DOI: 10.1016/j.jhep.2017.03.006
Quinn, K., Traboni, C., Penchala, S. D., Bouliotis, G., Doyle, N., Libri, V., . . . Winston, A. (2017). A first-in-human study of the novel HIV-fusion inhibitor C34-PEG<sub>4</sub>-Chol. SCIENTIFIC REPORTS, 7. doi:10.1038/s41598-017-09230-0DOI: 10.1038/s41598-017-09230-0
Waitt, C., Penchala, S. D., Olagunju, A., Amara, A., Else, L., Lamorde, M., & Khoo, S. (2017). Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. Journal of Chromatography B, 1060, 300-307. doi:10.1016/j.jchromb.2017.06.012DOI: 10.1016/j.jchromb.2017.06.012
Seden, K., Boffito, M., & Khoo, S. (2017). Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries. CURRENT OPINION IN HIV AND AIDS, 12(4), 377-382. doi:10.1097/COH.0000000000000384DOI: 10.1097/COH.0000000000000384
Sloan, D. J., McCallum, A. D., Schipani, A., Egan, D., Mwandumba, H. C., Ward, S. A., . . . Davies, G. R. (2017). Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(7). doi:10.1128/AAC.00210-17DOI: 10.1128/aac.00210-17
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (Journal article)
Elliot, E. R., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(7), 2035-2041. doi:10.1093/jac/dkx108DOI: 10.1093/jac/dkx108
Elliot, E. R., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (vol 72, pg 2035, 2017). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(7), 2143. doi:10.1093/jac/dkx145DOI: 10.1093/jac/dkx145
Roberts, O., Khoo, S., Owen, A., & Siccardi, M. (2017). Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(5). doi:10.1128/AAC.01776-16DOI: 10.1128/aac.01776-16
Gotham, D., Fortunak, J., Pozniak, A., Khoo, S., Cooke, G., Nytko, F. E. I. I. I., & Hill, A. (2017). Estimated generic prices for novel treatments for drug-resistant tuberculosis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(4), 1243-1252. doi:10.1093/jac/dkw522DOI: 10.1093/jac/dkw522
Genome-Wide Association Study of Nevirapine Hypersensitivity in a sub-Saharan African HIV-infected Population (Journal article)
Carr, D. F., Bourgeois, S., Chaponda, M., Takeshita, L., Morris, A., Cornejo Castro, E. M., . . . Pirmohamed, M. (2017). Genome-Wide Association Study of Nevirapine Hypersensitivity in a sub-Saharan African HIV-infected Population. Journal of Antimicrobial Chemotherapy, 72(4), 1152-1162. doi:10.1093/jac/dkw545DOI: 10.1093/jac/dkw545
Seden, K., Gibbons, S., Marzolini, C., Schapiro, J. M., Burger, D. M., Back, D. J., & Khoo, S. H. (2017). Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLOS ONE, 12(3). doi:10.1371/journal.pone.0173509DOI: 10.1371/journal.pone.0173509
ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine. (Conference Paper)
Bracchi, M., Neary, M. G., Pagani, N., Else, L., Khoo, S., Abbas, Z., . . . Boffito, M. (n.d.). ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.. In CROI. Seattle, WA, USA.
Guaraldi, G., Menozzi, M., Zona, S., Calcagno, A., Silva, A. R., Santoro, A., . . . Khoo, S. H. (2017). Impact of polypharmacy on antiretroviral prescription in people living with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(2), 511-514. doi:10.1093/jac/dkw437DOI: 10.1093/jac/dkw437
An open-label multiple-dose phase 1 assessment of long-acting rilpivirine (Conference Paper)
McGowan, I., Dezzutti, C. S., Siegel, A., Engstrom, J., Shetler, C., Richardson-Harman, N., . . . Cranston, R. D. (2017). An open-label multiple-dose phase 1 assessment of long-acting rilpivirine. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 20 (pp. 31). Retrieved from https://www.webofscience.com/
Case report: atazanavir associated cholelithiasis (Conference Paper)
Howlett, P., Simons, R., Wilkinson, M., Kulasegaram, R., Elsie, L., & Khoo, S. (2017). Case report: atazanavir associated cholelithiasis. In HIV MEDICINE Vol. 18 (pp. 15). Retrieved from https://www.webofscience.com/
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study (Journal article)
Amara, A. B., Else, L. J., Carey, D., Khoo, S., Back, D. J., Amin, J., . . . Puls, R. L. (2017). Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study. THERAPEUTIC DRUG MONITORING, 39(6), 654-658. doi:10.1097/FTD.0000000000000448DOI: 10.1097/FTD.0000000000000448
Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies (Conference Paper)
Marra, F., Siederdissen, C. H. Z., Khoo, S., Cornberg, M., Schlag, M., Ouwerkerk-Mahadevan, S., . . . Back, D. (2017). Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies. In JOURNAL OF HEPATOLOGY Vol. 66 (pp. S314). Retrieved from https://www.webofscience.com/
Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women (Journal article)
Khoo, S., Peytavin, G., Burger, D., Hill, A., Brown, K., Moecklinghoff, C., . . . Hadacek, M. B. (2017). Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women. AIDS REVIEWS, 19(1), 16-23. Retrieved from https://www.webofscience.com/
2016
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia (Journal article)
Nightingale, S., Geretti, A. M., Beloukas, A., Fisher, M., Winston, A., Else, L., . . . Khoo, S. (2016). Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. Journal of NeuroVirology, 22, 852-860. doi:10.1007/s13365-016-0448-1DOI: 10.1007/s13365-016-0448-1
McGowan, I., Dezzutti, C. S., Siegel, A., Engstrom, J., Nikiforov, A., Duffill, K., . . . Cranston, R. D. (2016). Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. LANCET HIV, 3(12), E569-E578. doi:10.1016/S2352-3018(16)30113-8DOI: 10.1016/S2352-3018(16)30113-8
Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.. Journal of acquired immune deficiency syndromes (1999), 73(3), 252-257. doi:10.1097/qai.0000000000001108DOI: 10.1097/qai.0000000000001108
Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 73(3), 252-257. Retrieved from https://www.webofscience.com/
McCallum, A. D., Nyirenda, D., Lora, W., Khoo, S. H., Sloan, D. J., Mwandumba, H. C., . . . Davies, G. R. (2016). Perceptions of Research Bronchoscopy in Malawian Adults with Pulmonary Tuberculosis: A Cross-Sectional Study. PLOS ONE, 11(10). doi:10.1371/journal.pone.0165734DOI: 10.1371/journal.pone.0165734
Steady-state pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 hours in healthy volunteers: the importance of PK forgiveness in clinical practice (Conference Paper)
Elliot, E., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2016). Steady-state pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 hours in healthy volunteers: the importance of PK forgiveness in clinical practice. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from https://www.webofscience.com/
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (Journal article)
Churchill, D., Waters, L., Ahmed, N., Angus, B., Boffito, M., Bower, M., . . . Winston, A. (2016). British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV MEDICINE, 17, S2-S104. doi:10.1111/hiv.12426DOI: 10.1111/hiv.12426
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis (Journal article)
Nightingale, S., Chau, T. T. H., Fisher, M., Nelson, M., Winston, A., Else, L., . . . Grp, P. -V. S. (2016). Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. Antimicrobial Agents and Chemotherapy, 60(8), 4511-4518. doi:10.1128/AAC.00280-16DOI: 10.1128/AAC.00280-16
Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study (Journal article)
Olagunju, A., Bolaji, O., Neary, M., Back, D., Khoo, S., & Owen, A. (2016). Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study. PHARMACOGENETICS AND GENOMICS, 26(8), 381-389. doi:10.1097/FPC.0000000000000227DOI: 10.1097/FPC.0000000000000227
Penchala, S. D., Fawcett, S., Else, L., Egan, D., Amara, A., Elliot, E., . . . Khoo, S. (2016). The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1027, 174-180. doi:10.1016/j.jchromb.2016.05.040DOI: 10.1016/j.jchromb.2016.05.040
CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF (Journal article)
Nightingale, S., Michael, B. D., Fisher, M., Winston, A., Nelson, M., Taylor, S., . . . Solomon, T. (2016). CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. Cytokine, 83, 139-146. doi:10.1016/j.cyto.2016.04.004DOI: 10.1016/j.cyto.2016.04.004
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications (Journal article)
Marzolini, C., Gibbons, S., Khoo, S., & Back, D. (2016). Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(7), 1755-1758. doi:10.1093/jac/dkw032DOI: 10.1093/jac/dkw032
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5DOI: 10.1007/s40262-015-0360-5
Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis (Journal article)
Olagunju, A., Khoo, S., & Owen, A. (2016). Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. PHARMACOGENOMICS, 17(8), 891-906. doi:10.2217/pgs-2015-0016DOI: 10.2217/pgs-2015-0016
Lewis, J. M., Railton, E., Riordan, A., Khoo, S., & Chaponda, M. (2016). Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing. AIDS, 30(8), 1313-1315. doi:10.1097/QAD.0000000000001055DOI: 10.1097/QAD.0000000000001055
Lewis, J. M., Hine, P., Walker, J., Khoo, S. H., Taegtmeyer, M., Squire, S. B., & Sloan, D. J. (2016). First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB. EUROPEAN RESPIRATORY JOURNAL, 47(5), 1581-1584. doi:10.1183/13993003.01980-2015DOI: 10.1183/13993003.01980-2015
Schipani, A., Pertinez, H., Mlota, R., Molyneux, E., Lopez, N., Dzinjalamala, F. K., . . . Davies, G. (2016). A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 81(4), 679-687. doi:10.1111/bcp.12848DOI: 10.1111/bcp.12848
Stott, K. E., Singh, B., Beadsworth, M. B. J., Vaudrey, K., Khoo, S. H., & Davies, G. (2016). Adequacy of Rifampin Absorption after Jejunostomy Tube Administration. PHARMACOTHERAPY, 36(4), E23-E25. doi:10.1002/phar.1730DOI: 10.1002/phar.1730
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake (Journal article)
Elliot, E., Amara, A., Jackson, A., Moyle, G., Else, L., Khoo, S., . . . Boffito, M. (2016). Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1031-1036. doi:10.1093/jac/dkv425DOI: 10.1093/jac/dkv425
Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients. (Journal article)
Gathogo, E., Harber, M., Bhagani, S., Levy, J., Jones, R., Hilton, R., . . . UK HIV Kidney Transplantation Study Group. (2016). Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.. Transplantation, 100(4), 871-878. doi:10.1097/tp.0000000000000879DOI: 10.1097/tp.0000000000000879
Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease (Journal article)
Molto, J., Graterol, F., Miranda, C., Khoo, S., Bancu, I., Amara, A., . . . Clotet, B. (2016). Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(4), 2564-2566. doi:10.1128/AAC.03131-15DOI: 10.1128/AAC.03131-15
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1041-1045. doi:10.1093/jac/dkv439DOI: 10.1093/jac/dkv439
Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports (Journal article)
Fox, J., Brady, M., Alexander, H., Davies, O., Robinson, N., Pace, M., . . . Frater, J. (2016). Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. INFECTIOUS DISEASES AND THERAPY, 5(1), 65-71. doi:10.1007/s40121-015-0102-xDOI: 10.1007/s40121-015-0102-x
Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro (Conference Paper)
Roberts, O., Back, D., Khoo, S., Owen, A., & Siccardi, M. (2016). Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro. In CROI. Boston, USA.
Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know? (Journal article)
Vitoria, M., Hill, A. M., Ford, N. P., Doherty, M., Khoo, S. H., & Pozniak, A. L. (2016). Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 19. doi:10.7448/IAS.19.1.20504DOI: 10.7448/IAS.19.1.20504
Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort (Journal article)
Lewis, J. M., Stott, K. E., Monnery, D., Seden, K., Beeching, N. J., Chaponda, M., . . . Beadsworth, M. B. J. (2016). Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort. INTERNATIONAL JOURNAL OF STD & AIDS, 27(2), 105-109. doi:10.1177/0956462415574632DOI: 10.1177/0956462415574632
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial (Journal article)
McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., . . . Gill, O. N. (2016). Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet, 387(10013), 53-60. doi:10.1016/S0140-6736(15)00056-2DOI: 10.1016/S0140-6736(15)00056-2
A first-in-human study, in HIV-positive men, of the novel HIV-fusion inhibitor C34-PEG4-Chol (Journal article)
Quinn, K., Bouliotis, G., Doyle, N., Winston, A., Ashby, D., Weber, J., . . . Pessi, A. (2016). A first-in-human study, in HIV-positive men, of the novel HIV-fusion inhibitor C34-PEG4-Chol. HIV MEDICINE, 17, 18. Retrieved from https://www.webofscience.com/
DETERMINATION OF LEDIPASVIR CONCENTRATIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS RECEIVING LOW DOSE PROTON PUMP INHIBITORS DURING SOFOSBUVIR-LEDIPASVIR TREATMENT FOR HCV GENOTYPE 1 INFECTION (Conference Paper)
El-Sherif, O., Stewart, S., Bergin, C., McKiernan, S., Crosbie, O., Khoo, S., & Norris, S. (2016). DETERMINATION OF LEDIPASVIR CONCENTRATIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS RECEIVING LOW DOSE PROTON PUMP INHIBITORS DURING SOFOSBUVIR-LEDIPASVIR TREATMENT FOR HCV GENOTYPE 1 INFECTION. In JOURNAL OF HEPATOLOGY Vol. 64 (pp. S805-S806). doi:10.1016/S0168-8278(16)01573-7DOI: 10.1016/S0168-8278(16)01573-7
Lewis, J. M., Volny-Anne, A., Waitt, C., Boffito, M., & Khoo, S. (2016). Dosing antiretroviral medication when crossing time zones: a review. AIDS, 30(2), 267-271. doi:10.1097/QAD.0000000000000920DOI: 10.1097/QAD.0000000000000920
Persistence of rilpivirine following single dose of long-acting injection (Conference Paper)
McGowan, I., Siegel, A., Engstrom, J., Nikiforov, A., Duffill, K., Edick, S., . . . Cranston, R. D. (2016). Persistence of rilpivirine following single dose of long-acting injection. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from https://www.webofscience.com/
Dickinson, L., Bracchi, M., Elliot, E., Else, L., Khoo, S., Back, D., . . . Boffito, M. (2016). Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from https://www.webofscience.com/
Single dose Maraviroc provides high drug levels in all sites; no gender differences (Journal article)
Tiraboschi, J., Davies, O., Fox, J., Else, L., Egan, D., Amara, A., . . . Boffito, M. (2016). Single dose Maraviroc provides high drug levels in all sites; no gender differences. HIV MEDICINE, 17, 17. Retrieved from https://www.webofscience.com/
2015
Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults (Journal article)
Seng, K. -Y., Hee, K. -H., Soon, G. -H., Chew, N., Khoo, S. H., & Lee, L. S. -U. (2015). Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3298-3306. doi:10.1093/jac/dkv268DOI: 10.1093/jac/dkv268
Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda (Journal article)
Seden, K., Merry, C., Hewson, R., Siccardi, M., Lamorde, M., Byakika-Kibwika, P., . . . Khoo, S. H. (2015). Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3317-3322. doi:10.1093/jac/dkv259DOI: 10.1093/jac/dkv259
Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers (Journal article)
Seng, K. -Y., Hee, K. -H., Soon, G. -H., Chew, N., Khoo, S. H., & Lee, L. S. -U. (2015). Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(11), 6791-6799. doi:10.1128/AAC.01244-15DOI: 10.1128/AAC.01244-15
Pushpakom, S., Taylor, C., Kolamunnage-Dona, R., Spowart, C., Vora, J., Garcia Finana, M., . . . Pirmohamed, M. (2015). Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIVpositive individuals on combination antiretroviral therapy. BMJ Open, 5(10). doi:10.1136/bmjopen-2015-009566DOI: 10.1136/bmjopen-2015-009566
Dickinson, L., Yapa, H. M., Jackson, A., Moyle, G., Else, L., Amara, A., . . . Boffito, M. (2015). Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(10), 6080-6086. doi:10.1128/AAC.01441-15DOI: 10.1128/AAC.01441-15
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots (Journal article)
Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174DOI: 10.1093/jac/dkv174
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.. Clinical pharmacology and therapeutics, 98(4), 406-416. doi:10.1002/cpt.156DOI: 10.1002/cpt.156
Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection (Journal article)
El-Sherif, O., Khoo, S., & Solas, C. (2015). Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection. CURRENT OPINION IN HIV AND AIDS, 10(5), 348-354. doi:10.1097/COH.0000000000000185DOI: 10.1097/COH.0000000000000185
Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety (Journal article)
Bracchi, M., Stuart, D., Castles, R., Khoo, S., Back, D., & Boffito, M. (2015). Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety. AIDS, 29(13), 1585-1592. doi:10.1097/QAD.0000000000000786DOI: 10.1097/QAD.0000000000000786
Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317DOI: 10.1093/cid/civ317
Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes (Journal article)
Sloan, D. J., Mwandumba, H. C., Kamdolozi, M., Shani, D., Chisale, B., Dutton, J., . . . Davies, G. R. (2015). Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 19(8), 904-911. doi:10.5588/ijtld.15.0071DOI: 10.5588/ijtld.15.0071
Sloan, D. J., Mwandumba, H. C., Kamdolozi, M., Shani, D., Chisale, B., Dutton, J., . . . Davies, G. R. (2015). Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes. The International Journal of Tuberculosis and Lung Disease, 19(8), 904-911. doi:10.5588/ijtld.15.0071DOI: 10.5588/ijtld.15.0071
Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis (Journal article)
Cummins, N. W., Neuhaus, J., Chu, H., Neaton, J., Wyen, C., Rockstroh, J. K., . . . Badley, A. D. (2015). Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBIOMEDICINE, 2(7), 706-712. doi:10.1016/j.ebiom.2015.05.012DOI: 10.1016/j.ebiom.2015.05.012
Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies (Journal article)
Waitt, C. J., Garner, P., Bonnett, L. J., Khoo, S. H., & Else, L. J. (2015). Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(7), 1928-1941. doi:10.1093/jac/dkv080DOI: 10.1093/jac/dkv080
Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis (Journal article)
Sloan, D. J., Mwandumba, H. C., Garton, N. J., Khoo, S. H., Butterworth, A. E., Allain, T. J., . . . Davies, G. R. (2015). Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis. Clinical Infectious Diseases, 61(1), 1-8. doi:10.1093/cid/civ195DOI: 10.1093/cid/civ195
Second European Round Table on the Future Management of HIV 10-11 October 2014, Barcelona, Spain (Journal article)
Rokx, C., Richman, D. D., Muller-Trutwin, M., Silvestri, G., van Lunzen, J., Khoo, S., . . . Boucher, C. A. B. (2015). Second European Round Table on the Future Management of HIV 10-11 October 2014, Barcelona, Spain. JOURNAL OF VIRUS ERADICATION, 1(3), 211-220. Retrieved from https://www.webofscience.com/
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study (Journal article)
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers (Journal article)
Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Cooke, G., . . . Winston, A. (2015). A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(6), 1812-1815. doi:10.1093/jac/dkv035DOI: 10.1093/jac/dkv035
Else, L., Back, D., Khoo, S. H., & Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.. The Journal of Antimicrobial Chemotherapy, 70(5), 1482-1486. doi:10.1093/jac/dku575DOI: 10.1093/jac/dku575
Amara, A. B., Else, L. J., Tjia, J., Olagunju, A., Puls, R. L., Khoo, S., & Back, D. J. (2015). A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography-Mass Spectrometry. THERAPEUTIC DRUG MONITORING, 37(2), 220-228. doi:10.1097/FTD.0000000000000127DOI: 10.1097/FTD.0000000000000127
Winston, A., Amin, J., Clarke, A., Else, L., Amara, A., Owen, A., . . . Puls, R. (2015). Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 60(7), 1026-1032. doi:10.1093/cid/ciu976DOI: 10.1093/cid/ciu976
Minimum Target Prices for Production of Direct-Acting Antivirals and Associated Diagnostics to Combat Hepatitis C Virus (Journal article)
van de Ven, N., Fortunak, J., Simmons, B., Ford, N., Cooke, G. S., Khoo, S., & Hill, A. (2015). Minimum Target Prices for Production of Direct-Acting Antivirals and Associated Diagnostics to Combat Hepatitis C Virus. HEPATOLOGY, 61(4), 1174-1182. doi:10.1002/hep.27641DOI: 10.1002/hep.27641
Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43DOI: 10.1002/cpt.43
A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS (Journal article)
Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Graham, C., . . . Winston, A. (2015). A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS. SEXUALLY TRANSMITTED INFECTIONS, 91, A78. doi:10.1136/sextrans-2015-052126.231DOI: 10.1136/sextrans-2015-052126.231
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420DOI: 10.1093/jac/dku420
Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir (Journal article)
Reynolds, H. E., Chrdle, A., Egan, D., Chaponda, M., Else, L., Chiong, J., . . . Khoo, S. H. (2015). Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 550-554. doi:10.1093/jac/dku376DOI: 10.1093/jac/dku376
A Phase IV HIV PrEP study reveals limited ex vivo potency of oral Maraviroc against HIV-1 (Journal article)
Tiraboschi, J., Fox, J., Herrera, C., Olejniczak, N., Jackson, A., Boffito, M., . . . Shattock, R. (2015). A Phase IV HIV PrEP study reveals limited ex vivo potency of oral Maraviroc against HIV-1. HIV MEDICINE, 16, 3-4. Retrieved from https://www.webofscience.com/
CSF:plasma HIV-1 RNA discordance >0.5 log<sub>10</sub> is associated with raised inflammatory mediator profiles in CSF (Journal article)
Nightingale, S., Michael, B., King, S., Beloukas, A., Pirmohamed, M., Geretti, A. M., . . . Post, F. (2015). CSF:plasma HIV-1 RNA discordance >0.5 log<sub>10</sub> is associated with raised inflammatory mediator profiles in CSF. HIV MEDICINE, 16, 7. Retrieved from https://www.webofscience.com/
Determination of on-treatment pharmacokinetics of sofosbuvir and ledipasvir in patients with decompensated cirrhosis - the need for real world PK studies (Conference Paper)
El-Sherif, O., Houlihan, D. D., Stewart, S., Bergin, C. J., Fanning, L. J., McKiernan, S., . . . Khoo, S. H. (2015). Determination of on-treatment pharmacokinetics of sofosbuvir and ledipasvir in patients with decompensated cirrhosis - the need for real world PK studies. In HEPATOLOGY Vol. 62 (pp. 752A). Retrieved from https://www.webofscience.com/
Developing a new virtual HIV network: Our region's experience (Journal article)
Wolujewicz, A., Lewis, J., Chaponda, M., Chiong, J., & Khoo, S. (2015). Developing a new virtual HIV network: Our region's experience. HIV MEDICINE, 16, 69-70. Retrieved from https://www.webofscience.com/
Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy: need for "real world" PK studies to identify vulnerable populations (Journal article)
El-Sherif, O., Dilly, P. S., Else, L., McKiernan, S., Khoo, S., & Norris, S. (2015). Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy: need for "real world" PK studies to identify vulnerable populations. IRISH JOURNAL OF MEDICAL SCIENCE, 184, S218. Retrieved from https://www.webofscience.com/
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults (Journal article)
Lamorde, M., Walimbwa, S., Byakika-Kibwika, P., Katwere, M., Mukisa, L., Sempa, J. B., . . . Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother, 70(5), 1482-1486.
Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine (Journal article)
Schipani, A., Back, D., Owen, A., Davies, G., Khoo, S., & Siccardi, M. (2015). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. CLINICAL PHARMACOKINETICS, 54(1), 107-116. doi:10.1007/s40262-014-0184-8DOI: 10.1007/s40262-014-0184-8
2014
Carr, D. F., Chaponda, M., Cornejo Castro, E. M., Jorgensen, A. L., Khoo, S., Van Oosterhout, J. J., . . . Pirmohamed, M. (2014). CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. Journal of Antimicrobial Chemotherapy, 69(12), 3329-3334. doi:10.1093/jac/dku315DOI: 10.1093/jac/dku315
Hepatitis B Virus Sub-genotype A1 Infection Is Characterized by High Replication Levels and Rapid Emergence of Drug Resistance in HIV-Positive Adults Receiving First-line Antiretroviral Therapy in Malawi (Journal article)
Aoudjane, S., Chaponda, M., Gonzalez Del Castillo, A. A., O'Connor, J., Noguera, M., Beloukas, A., . . . Geretti, A. M. (2014). Hepatitis B Virus Sub-genotype A1 Infection Is Characterized by High Replication Levels and Rapid Emergence of Drug Resistance in HIV-Positive Adults Receiving First-line Antiretroviral Therapy in Malawi. Clinical Infectious Diseases, 59(11), 1618-1626. doi:10.1093/cid/ciu630DOI: 10.1093/cid/ciu630
RISK FACTORS AND THERAPEUTIC IMPLICATIONS OF VITAMIN D DEFICIENCY IN MALAWIAN ADULTS WITH PULMONARY TUBERCULOSIS (Conference Paper)
Sloan, D. J., Guwende, C., Banda, G., Shani, D., Kamdolozi, M., Chisale, B., . . . Davies, G. R. (2014). RISK FACTORS AND THERAPEUTIC IMPLICATIONS OF VITAMIN D DEFICIENCY IN MALAWIAN ADULTS WITH PULMONARY TUBERCULOSIS. In THORAX Vol. 69 (pp. A42). doi:10.1136/thoraxjnl-2014-206260.81DOI: 10.1136/thoraxjnl-2014-206260.81
A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops (Journal article)
Lewis, J., Turtle, L., Khoo, S., & Nsutebu, E. (2014). A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops. AIDS, 28(17), 2636-2637. doi:10.1097/QAD.0000000000000462DOI: 10.1097/QAD.0000000000000462
Darunavir pharmacokinetics throughout pregnancy and postpartum (Journal article)
Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. J Int AIDS Soc, 17(4 Supp), 19485.
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant (Journal article)
Scarsi, K., Lamorde, M., Darin, K., Dilly Penchala, S., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc, 17(4 Supp), 19484.
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach (Journal article)
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach. Journal of the International AIDS Society, 17(4S3). doi:10.7448/ias.17.4.19586DOI: 10.7448/ias.17.4.19586
Controversies in HIV-associated neurocognitive disorders (Journal article)
Nightingale, S., Winston, A., Letendre, S., Michael, B. D., McArthur, J. C., Khoo, S., & Solomon, T. (2014). Controversies in HIV-associated neurocognitive disorders. LANCET NEUROLOGY, 13(11), 1139-1151. doi:10.1016/S1474-4422(14)70137-1DOI: 10.1016/S1474-4422(14)70137-1
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant (Journal article)
Scarsi, K., Lamorde, M., Darin, K., Penchala, S. D., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17, 4. doi:10.7448/IAS.17.4.19484DOI: 10.7448/IAS.17.4.19484
Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy (Journal article)
Else, L. J., Jackson, V., Brennan, M., Back, D. J., Khoo, S. H., Coulter-Smith, S., & Lambert, J. S. (2014). Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. HIV MEDICINE, 15(10), 604-610. doi:10.1111/hiv.12164DOI: 10.1111/hiv.12164
No pharmacokinetic interaction between raltegravir and amlodipine (Journal article)
Singh, G. J., Jackson, A., D’Avolio, A., Else, L., De Nicolò, A., Bonora, S., . . . Boffito, M. (2014). No pharmacokinetic interaction between raltegravir and amlodipine. AIDS, 28(13), 1993-1995. doi:10.1097/qad.0000000000000356DOI: 10.1097/qad.0000000000000356
No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals (Journal article)
Singh, G. J., Jackson, A., D'Avolio, A., Else, L., De Nicolo, A., Bonora, S., . . . Boffito, M. (2014). No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. AIDS, 28(13), 1993-1995. doi:10.1097/QAD.0000000000000356DOI: 10.1097/QAD.0000000000000356
HIV Associated Neurocognitive Disorders (HAND) in Malawian Adults and Effect on Adherence to Combination Anti-Retroviral Therapy: A Cross Sectional Study (Journal article)
Kelly, C. M., van Oosterhout, J. J., Ngwalo, C., Stewart, R. C., Benjamin, L., Robertson, K. R., . . . Solomon, T. (2014). HIV Associated Neurocognitive Disorders (HAND) in Malawian Adults and Effect on Adherence to Combination Anti-Retroviral Therapy: A Cross Sectional Study. PLOS ONE, 9(6). doi:10.1371/journal.pone.0098962DOI: 10.1371/journal.pone.0098962
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy (Journal article)
Mora-Peris, B., Watson, V., Vera, J. H., Weston, R., Waldman, A. D., Kaye, S., . . . Winston, A. (2014). Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(6), 1642-1647. doi:10.1093/jac/dku018DOI: 10.1093/jac/dku018
Abacavir forms novel cross-linking abacavir protein adducts in patients (Journal article)
Meng, X., Lawrenson, A. S., Berry, N. G., Maggs, J. L., French, N. S., Back, D. J., . . . Park, B. K. (2014). Abacavir forms novel cross-linking abacavir protein adducts in patients. Chemical Research in Toxicology, 27(04), 524-535. doi:10.1021/tx400406pDOI: 10.1021/tx400406p
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries (Journal article)
Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014). Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clinical Infectious Diseases, 58(7), 928-936. doi:10.1093/cid/ciu012DOI: 10.1093/cid/ciu012
Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity (Journal article)
Yombi, J. C., Pozniak, A., Boffito, M., Jones, R., Khoo, S., Levy, J., & Post, F. A. (2014). Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS, 28(5), 621-632. doi:10.1097/QAD.0000000000000103DOI: 10.1097/QAD.0000000000000103
Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation (Journal article)
McDonald, T. O., Giardiello, M., Martin, P., Siccardi, M., Liptrott, N. J., Roberts, P., . . . Owen, A. (2014). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials, 3(3), 400-411. doi:10.1002/adhm.201300280DOI: 10.1002/adhm.201300280
Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection (Journal article)
Karageorgopoulos, D. E., El-Sherif, O., Bhagani, S., & Khoo, S. H. (2014). Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. CURRENT OPINION IN INFECTIOUS DISEASES, 27(1), 36-45. doi:10.1097/QCO.0000000000000034DOI: 10.1097/QCO.0000000000000034
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients (Journal article)
Sarfo, F. S., Zhang, Y., Egan, D., Tetteh, L. A., Phillips, R., Bedu-Addo, G., . . . Chadwick, D. R. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(2), 491-499. doi:10.1093/jac/dkt372DOI: 10.1093/jac/dkt372
Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi (Journal article)
Dickinson, L., Chaponda, M., Carr, D. F., van Oosterhout, J. J., Kumwenda, J., Lalloo, D. G., . . . Khoo, S. H. (2014). Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(2), 706-712. doi:10.1128/AAC.02069-13DOI: 10.1128/AAC.02069-13
<i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults (Journal article)
Olagunju, A., Schipani, A., Siccardi, M., Egan, D., Khoo, S., Back, D., & Owen, A. (2014). <i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. PHARMACOGENETICS AND GENOMICS, 24(9), 459-463. doi:10.1097/FPC.0000000000000073DOI: 10.1097/FPC.0000000000000073
An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database) (Journal article)
Danjuma, M. I., Mohamad-Fadzillah, N. H., & Khoo, S. (2014). An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database). INTERNATIONAL JOURNAL OF STD & AIDS, 25(4), 273-279. doi:10.1177/0956462413504747DOI: 10.1177/0956462413504747
Darunavir pharmacokinetics throughout pregnancy and postpartum (Poster)
Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. Poster session presented at the meeting of Unknown Conference. Retrieved from https://www.webofscience.com/DOI: 10.7448/IAS.17.4.19485
Scarsi, K., Lamorde, M., Darin, K., Penchala, S. D., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant.. doi:10.7448/ias.17.4.19484DOI: 10.7448/ias.17.4.19484
Kidney transplantation in HIV-positive adults: the UK experience (Journal article)
Gathogo, E. N., Hamzah, L., Hilton, R., Marshall, N., Ashley, C., Harber, M., . . . Post, F. A. (2014). Kidney transplantation in HIV-positive adults: the UK experience. INTERNATIONAL JOURNAL OF STD & AIDS, 25(1), 57-66. doi:10.1177/0956462413493266DOI: 10.1177/0956462413493266
Minimum target prices for production of Direct Acting Antivirals and associated diagnostics for developing countries (Conference Paper)
Hill, A. M., van de Ven, N. S., Simmons, B., Ford, N., Khoo, S. H., & Fortunak, J. M. (2014). Minimum target prices for production of Direct Acting Antivirals and associated diagnostics for developing countries. In HEPATOLOGY Vol. 60 (pp. 233A-234A). Retrieved from https://www.webofscience.com/
Dunning, J. W., Merson, L., Rohde, G. G. U., Gao, Z., Semple, M. G., Dat, T., . . . Baillie, J. K. (2014). Open source clinical science for emerging infections. LANCET INFECTIOUS DISEASES, 14(1), 8-9. doi:10.1016/S1473-3099(13)70327-XDOI: 10.1016/S1473-3099(13)70327-X
Pharmacokinetic Variability in TB Therapy: Associations With HIV and Effect On Outcome (Journal article)
Sloan, D. J., Schipani, A., Waterhouse, D., Stone, L., Mwandumba, H. C., Butterworth, A. E., . . . Davies, G. R. (2014). Pharmacokinetic Variability in TB Therapy: Associations With HIV and Effect On Outcome. Topics in Antiviral Medicine, 22(e-1), 55. Retrieved from https://www.iasusa.org/tam/april-2014
Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers (Journal article)
Singh, G. K. J., Jackson, A., D'Avolio, A., Else, L., Bonora, S., Di Perri, G., . . . Boffito, M. (2014). Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers. HIV MEDICINE, 15, 115. Retrieved from https://www.webofscience.com/
Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry (Journal article)
Else, L. J., Tjia, J., Jackson, A., Penchala, S. D., Egan, D., Boffito, M., . . . Back, D. J. (2014). Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry. BIOANALYSIS, 6(14), 1907-1921. doi:10.4155/BIO.14.59DOI: 10.4155/BIO.14.59
Severe virologic expression of hepatitis B virus (HBV) co-infection in HIV-positive adults starting antiretroviral therapy (ART) in Malawi (Conference Paper)
Geretti, A. M., Aoudjane, S., Chaponda, M., Gonzalez del Castillo, A., O'Connor, J., Noguera, M., . . . van Oosterhout, J. (2014). Severe virologic expression of hepatitis B virus (HBV) co-infection in HIV-positive adults starting antiretroviral therapy (ART) in Malawi. In ANTIVIRAL THERAPY Vol. 19 (pp. A36). Retrieved from https://www.webofscience.com/
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors? (Journal article)
Hill, A., Khoo, S., Back, D., Pozniak, A., & Boffito, M. (2014). Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?. J Int AIDS Soc, 17(4 Supp), 19583.
Should the dose of tenofovir be reduced to 200-250mg/day, when combined with protease inhibitors? (Journal article)
Hill, A., Khoo, S., Back, D., Pozniak, A., & Boffito, M. (2014). Should the dose of tenofovir be reduced to 200-250mg/day, when combined with protease inhibitors?. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17, 64-65. doi:10.7448/IAS.17.4.19583DOI: 10.7448/IAS.17.4.19583
Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy - need for "real world" PK studies to identify vulnerable populations (Conference Paper)
El-Sherif, O., Penchala, S. D., Else, L. J., Norris, S., & Khoo, S. H. (2014). Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy - need for "real world" PK studies to identify vulnerable populations. In HEPATOLOGY Vol. 60 (pp. 689A). Retrieved from https://www.webofscience.com/
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach (Journal article)
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. J Int AIDS Soc, 17(4 Supp), 19586.
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.. Journal of the International AIDS Society, 17(4 Suppl 3), 19586. doi:10.7448/ias.17.4.19586DOI: 10.7448/ias.17.4.19586
Special Issue: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update) (Journal article)
Williams, I., Churchill, D., Anderson, J., Boffito, M., Bower, M., Cairns, G., . . . Youle, M. (2014). Special Issue: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update). HIV MEDICINE, 15, 1-85. doi:10.1111/hiv.12119DOI: 10.1111/hiv.12119
Who accesses PrEP? An analysis of baseline data in the PROUD pilot (Journal article)
Dolling, D., Desai, M., Saunders, J., Mackie, N., McOwan, A., Youssef, E., . . . McCormack, S. (2014). Who accesses PrEP? An analysis of baseline data in the PROUD pilot. HIV MEDICINE, 15, 15. Retrieved from https://www.webofscience.com/
2013
Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation (Journal article)
Liptrott, N. J., Curley, P., Moss, D., Back, D. J., Khoo, S. H., & Owen, A. (2013). Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(11), 2545-2549. doi:10.1093/jac/dkt225DOI: 10.1093/jac/dkt225
New Drugs and Treatment Regimens (Journal article)
Sloan, D., Davies, G., & Khoo, S. (2013). New Drugs and Treatment Regimens. Current Respiratory Medicine Reviews, 9(3), 200-210. doi:10.2174/1573398x113099990017DOI: 10.2174/1573398x113099990017
Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: the pharmacometrics of infectious disease.. CPT: pharmacometrics & systems pharmacology, 2, e70. doi:10.1038/psp.2013.46DOI: 10.1038/psp.2013.46
Opinion: The Pharmacometrics of Infectious Disease (Journal article)
Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: The Pharmacometrics of Infectious Disease. CPT: Pharmacometrics & Systems Pharmacology, 2(8), 1-3. doi:10.1038/psp.2013.46DOI: 10.1038/psp.2013.46
Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients. (Journal article)
Westwood, T. D., Hogan, C., Julyan, P. J., Coutts, G., Bonington, S., Carrington, B., . . . Bonington, A. (2013). Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients.. European journal of radiology, 82(8), e374-e379. doi:10.1016/j.ejrad.2013.03.008DOI: 10.1016/j.ejrad.2013.03.008
Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer (Journal article)
Penchala, S. D., Tjia, J., El Sherif, O., Back, D. J., Khoo, S. H., & Else, L. J. (2013). Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 932, 100-110. doi:10.1016/j.jchromb.2013.06.013DOI: 10.1016/j.jchromb.2013.06.013
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach (Journal article)
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. CLINICAL PHARMACOKINETICS, 52(7), 583-592. doi:10.1007/s40262-013-0056-7DOI: 10.1007/s40262-013-0056-7
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. (Journal article)
Winston, A., Jose, S., Gibbons, S., Back, D., Stohr, W., Post, F., . . . UK Collaborative HIV Cohort Study. (2013). Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.. The Journal of antimicrobial chemotherapy, 68(6), 1354-1359. doi:10.1093/jac/dkt029DOI: 10.1093/jac/dkt029
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. (Journal article)
Mora-Peris, B., Croucher, A., Else, L. J., Vera, J. H., Khoo, S., Scullard, G., . . . Winston, A. (2013). Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.. The Journal of antimicrobial chemotherapy, 68(6), 1348-1353. doi:10.1093/jac/dkt006DOI: 10.1093/jac/dkt006
Recent advances in tuberculosis: New drugs and treatment regimens. (Journal article)
Sloan, D. J., Davies, G. R., & Khoo, S. H. (2013). Recent advances in tuberculosis: New drugs and treatment regimens.. Current respiratory medicine reviews, 9(3), 200-210. doi:10.2174/1573398x113099990017DOI: 10.2174/1573398x113099990017
Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population (Journal article)
Carr, D. F., Chaponda, M., Jorgensen, A. L., Castro, E. C., van Oosterhout, J. J., Khoo, S. H., . . . Pirmohamed, M. (2013). Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population. CLINICAL INFECTIOUS DISEASES, 56(9), 1330-1339. doi:10.1093/cid/cit021DOI: 10.1093/cid/cit021
Rilpivirine concentrations in seminal plasma in HIV infected patients (Poster)
Watson, V., Mora-Peris, B., Tjia, J., Vera, J. H., Weston, R., Khoo, S., . . . Winston, A. (2013). Rilpivirine concentrations in seminal plasma in HIV infected patients. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment (Journal article)
Lamorde, M., Byakika-Kibwika, P., Mayito, J., Nabukeera, L., Ryan, M., Hanpithakpong, W., . . . Merry, C. (2013). Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. AIDS, 27(6), 961-965. doi:10.1097/QAD.0b013e32835cae3bDOI: 10.1097/QAD.0b013e32835cae3b
Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases. (Journal article)
Seden, K., Khoo, S., Back, D., Prevatt, N., Lamorde, M., Byakika-Kibwika, P., . . . Merry, C. (2013). Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases.. AIDS (London, England), 27(5), 675-686. doi:10.1097/qad.0b013e32835ca9b4DOI: 10.1097/qad.0b013e32835ca9b4
The clinical utility of HIV outpatient pharmacist prescreening to reduce medication error and assess adherence. (Journal article)
Seden, K., Bradley, M., Miller, A. R. O., Beadsworth, M. B. J., & Khoo, S. H. (2013). The clinical utility of HIV outpatient pharmacist prescreening to reduce medication error and assess adherence.. International journal of STD & AIDS, 24(3), 237-241. doi:10.1177/0956462412472428DOI: 10.1177/0956462412472428
Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England (Journal article)
Seden, K., Kirkham, J. J., Kennedy, T., Lloyd, M., James, S., Mcmanus, A., . . . Khoo, S. H. (2013). Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England. BMJ OPEN, 3(1). doi:10.1136/bmjopen-2012-002036DOI: 10.1136/bmjopen-2012-002036
Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England (Journal article)
Seden, K., Kirkham, J. J., Kennedy, T., Lloyd, M., James, S., McManus, A., . . . Khoo, S. (2013). Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England. BMJ Open, 3(1).
Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. (Journal article)
Seden, K., Khoo, S. H., Back, D., Byakika-Kibwika, P., Lamorde, M., Ryan, M., & Merry, C. (2013). Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.. The Journal of antimicrobial chemotherapy, 68(1), 1-3. doi:10.1093/jac/dks346DOI: 10.1093/jac/dks346
New Drugs and Treatment Regimens for tuberculosis (Journal article)
Sloan, D. J., Davies, G. R., & Khoo, S. H. (2013). New Drugs and Treatment Regimens for tuberculosis. Current Respiratory Medicine Reviews, 9(3), 200-210.
Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach (Conference Paper)
Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies (Journal article)
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231DOI: 10.1097/QAI.0b013e3182737231
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies (Journal article)
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231DOI: 10.1097/QAI.0b013e3182737231
The pharmacometrics of infectious diseases (Journal article)
Davies, G. R., Khoo, S. H., & Hope, W. (2013). The pharmacometrics of infectious diseases. CPT: Pharmacometrics and systems pharmacology, 2, e70. Retrieved from cpt:%20pharmacomet.%20syst.%20pharmacol.%202:%20e70;%20doi:10.1038/psp.2013.46
2012
Lamorde, M., Byakika-Kibwika, P., Tamale, W. S., Kiweewa, F., Ryan, M., Amara, A., . . . Merry, C. (2012). Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.. AIDS research and treatment, 2012, 105980. doi:10.1155/2012/105980DOI: 10.1155/2012/105980
Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP) (Journal article)
Watson, V., Else, L., Tjia, J., Khoo, S., & Back, D. (2012). Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP). Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18336DOI: 10.7448/ias.15.6.18336
Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Boffito, M., . . . Back, D. (2012). Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV-infected patients: evaluation of lower ritonavir dose. Journal of the International AIDS Society, 15(4).
HIV infection and stroke: current perspectives and future directions (Journal article)
Benjamin, L. A., Bryer, A., Emsley, H. C. A., Khoo, S., Solomon, T., & Connor, M. D. (2012). HIV infection and stroke: current perspectives and future directions. LANCET NEUROLOGY, 11(10), 878-890. doi:10.1016/S1474-4422(12)70205-3DOI: 10.1016/S1474-4422(12)70205-3
Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults (Journal article)
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults. ANTIVIRAL THERAPY, 17(5), 861-868. doi:10.3851/IMP2095DOI: 10.3851/IMP2095
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. (Journal article)
Williams, I., Churchill, D., Anderson, J., Boffito, M., Bower, M., Cairns, G., . . . Youle, M. (2012). British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.. HIV medicine, 13 Suppl 2, 1-85. doi:10.1111/j.1468-1293.2012.01029.xDOI: 10.1111/j.1468-1293.2012.01029.x
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults (Journal article)
Byakika-Kibwika, P., Lamorde, M., Mayito, J., Nabukeera, L., Namakula, R., Mayanja-Kizza, H., . . . Merry, C. (2012). Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. Journal of Antimicrobial Chemotherapy, 67(9), 2213-2221. doi:10.1093/jac/dks207DOI: 10.1093/jac/dks207
Byakika-Kibwika, P., Lamorde, M., Mayito, J., Nabukeera, L., Namakula, R., Mayanja-Kizza, H., . . . Merry, C. (2012). Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.. The Journal of antimicrobial chemotherapy, 67(9), 2213-2221. doi:10.1093/jac/dks207DOI: 10.1093/jac/dks207
Optimizing Outpatient Serial Sputum Colony Counting for Studies of Tuberculosis Treatment in Resource-Poor Settings (Journal article)
Sloan, D. J., Corbett, E. L., Butterworth, A. E., Mwandumba, H. C., Khoo, S. H., Mdolo, A., . . . Davies, G. R. (2012). Optimizing Outpatient Serial Sputum Colony Counting for Studies of Tuberculosis Treatment in Resource-Poor Settings. JOURNAL OF CLINICAL MICROBIOLOGY, 50(7), 2315-2320. doi:10.1128/JCM.00043-12DOI: 10.1128/JCM.00043-12
Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults. (Journal article)
Lamorde, M., Byakika-Kibwika, P., Boffito, M., Nabukeera, L., Mayito, J., Ogwal-Okeng, J., . . . Merry, C. (2012). Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.. Journal of acquired immune deficiency syndromes (1999), 60(3), 295-298. doi:10.1097/qai.0b013e3182567a35DOI: 10.1097/qai.0b013e3182567a35
Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i> (Journal article)
Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 3020-3026. doi:10.1128/AAC.06407-11DOI: 10.1128/AAC.06407-11
Byakika-Kibwika, P., Lamorde, M., Okaba-Kayom, V., Mayanja-Kizza, H., Katabira, E., Hanpithakpong, W., . . . Merry, C. (2012). Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.. The Journal of antimicrobial chemotherapy, 67(5), 1217-1223. doi:10.1093/jac/dkr596DOI: 10.1093/jac/dkr596
Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF) (Poster)
Watson, V., Tjia, J., Szwandt, S., Else, L., Khoo, S., & Back, D. (2012). Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF). Poster session presented at the meeting of 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain.
Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study (Journal article)
Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(3), 1427-1433. doi:10.1128/AAC.05599-11DOI: 10.1128/AAC.05599-11
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study (Journal article)
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrobial Agents and Chemotherapy, 56(3), 1427-1433.
Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations (Journal article)
Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 816-824. doi:10.1128/AAC.05186-11DOI: 10.1128/AAC.05186-11
Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations (Journal article)
Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. Antimicrobial Agents and Chemotherapy, 56(2), 816-824. doi:10.1128/aac.05186-11DOI: 10.1128/aac.05186-11
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. (Journal article)
Else, L., Douglas, M., Dickinson, L., Back, D., Khoo, S., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.
Patients accessing HIV treatment via sexual health services: what are the risks of the dual case-note system? (Journal article)
Seden, K., Mathew, T., Bradley, M., Ferraro, C., Hall, E., Beeching, N. J., & Khoo, S. H. (2012). Patients accessing HIV treatment via sexual health services: what are the risks of the dual case-note system?. INTERNATIONAL JOURNAL OF STD & AIDS, 23(2), 99-104. doi:10.1258/ijsa.2011.011070DOI: 10.1258/ijsa.2011.011070
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects. (Journal article)
Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.. Antiviral therapy, 17(1), 19-24. doi:10.3851/imp1910DOI: 10.3851/imp1910
Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (Journal article)
Liptrott, N. J., Pushpakom, S., Wyen, C., Faetkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. PHARMACOGENETICS AND GENOMICS, 22(1), 10-19. doi:10.1097/FPC.0b013e32834dd82eDOI: 10.1097/FPC.0b013e32834dd82e
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (Journal article)
Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82eDOI: 10.1097/fpc.0b013e32834dd82e
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults (Journal article)
Lamorde, M., Byakika-Kibwika, P., Tamale, W. S., Kiweewa, F., Ryan, M., Amara, A., . . . Merry, C. (2012). Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. AIDS Research and Treatment, 2012, 1-6. doi:10.1155/2012/105980DOI: 10.1155/2012/105980
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults (Journal article)
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antiviral Therapy, 17(5), 861-868.
Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects (Journal article)
Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects. Antiviral Therapy, 17(1), 19-24. doi:10.3851/imp1910DOI: 10.3851/imp1910
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study (Journal article)
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.
2011
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid) (Journal article)
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ANTIVIRAL THERAPY, 16(8), 1139-1147. doi:10.3851/IMP1918DOI: 10.3851/IMP1918
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract (Journal article)
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. ANTIVIRAL THERAPY, 16(8), 1149-1167. doi:10.3851/IMP1919DOI: 10.3851/IMP1919
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals (Journal article)
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), 450-457. doi:10.1097/qai.0b013e3182364c67DOI: 10.1097/qai.0b013e3182364c67
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals (Journal article)
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(5), 450-457. doi:10.1097/QAI.0b013e3182364c67DOI: 10.1097/QAI.0b013e3182364c67
Should We Switch to a 50-mg Boosting Dose of Ritonavir for Selected Protease Inhibitors? (Journal article)
Hill, A., Khoo, S., Boffito, M., & Back, D. (2011). Should We Switch to a 50-mg Boosting Dose of Ritonavir for Selected Protease Inhibitors?. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), e137-e138. doi:10.1097/qai.0b013e318237ccaeDOI: 10.1097/qai.0b013e318237ccae
Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors? (Journal article)
Hill, A., Khoo, S., Boffito, M., & Back, D. (2011). Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?. Journal of acquired immune deficiency syndromes (1999), 58(5), e137-e138. doi:10.1097/qai.0b013e318237ccaeDOI: 10.1097/qai.0b013e318237ccae
Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract (Journal article)
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract. Antiviral Therapy, 16(8), 1149-1167. doi:10.3851/imp1919DOI: 10.3851/imp1919
Chapter 19: Interactions between Antituberculosis and Antiretroviral Agents (Chapter)
McIlleron, H., & Khoo, S. H. (2011). Chapter 19: Interactions between Antituberculosis and Antiretroviral Agents. In Antituberculosis Chemotherapy (pp. 191-202). S. Karger AG. doi:10.1159/000324217DOI: 10.1159/000324217
13 A‐Z of drugs used in the treatment of opportunist infections in HIV (Appendix 1) (Journal article)
Weston, R., & Khoo, S. (2011). 13 A‐Z of drugs used in the treatment of opportunist infections in HIV (Appendix 1). HIV Medicine, 12(s2), 112-139. doi:10.1111/j.1468-1293.2011.00944_14.xDOI: 10.1111/j.1468-1293.2011.00944_14.x
Ageing with HIV: medication use and risk for potential drug-drug interactions (Journal article)
Marzolini, C., Back, D., Weber, R., Furrer, H., Cavassini, M., Calmy, A., . . . Yerly, S. (2011). Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 66(9), 2107-2111. doi:10.1093/jac/dkr248DOI: 10.1093/jac/dkr248
British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. (Journal article)
Nelson, M., Dockrell, D., Edwards, S., BHIVA Guidelines Subcommittee., Angus, B., Barton, S., . . . Weston, R. (2011). British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011.. HIV medicine, 12 Suppl 2, 1-140. doi:10.1111/j.1468-1293.2011.00944_1.xDOI: 10.1111/j.1468-1293.2011.00944_1.x
Interactions between antituberculosis and antiretroviral agents (Book)
McIlleron, H., & Khoo, S. H. (2011). Interactions between antituberculosis and antiretroviral agents (Vol. 40). doi:10.1159/000324217DOI: 10.1159/000324217
Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation (Journal article)
Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. Antimicrobial Agents and Chemotherapy, 55(9), 4218-4223. doi:10.1128/aac.01747-10DOI: 10.1128/aac.01747-10
Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation (Journal article)
Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(9), 4218-4223. doi:10.1128/AAC.01747-10DOI: 10.1128/AAC.01747-10
Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction (Journal article)
Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. JOURNAL OF INFECTIOUS DISEASES, 204(1), 145-153. doi:10.1093/infdis/jir215DOI: 10.1093/infdis/jir215
Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction (Journal article)
Pushpakom, S. P., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. The Journal of Infectious Diseases, 204(1), 145-153. doi:10.1093/infdis/jir215DOI: 10.1093/infdis/jir215
Janneh, O., & Khoo, S. H. (2011). Interactions of tenofovir, Lamivudine, abacavir and Didanosine in primary human cells.. Pharmaceutics, 3(2), 326-337. doi:10.3390/pharmaceutics3020326DOI: 10.3390/pharmaceutics3020326
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals (Journal article)
Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . Back, D. J. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(6), 1332-1339. doi:10.1093/jac/dkr087DOI: 10.1093/jac/dkr087
Lopinavir/ritonavir population pharmacokinetics in neonates and infants (Journal article)
Urien, S., Firtion, G., Anderson, S. T., Hirt, D., Solas, C., Peytavin, G., . . . Tréluyer, J. (2011). Lopinavir/ritonavir population pharmacokinetics in neonates and infants. British Journal of Clinical Pharmacology, 71(6), 956-960. doi:10.1111/j.1365-2125.2011.03926.xDOI: 10.1111/j.1365-2125.2011.03926.x
Lopinavir/ritonavir population pharmacokinetics in neonates and infants. (Journal article)
Urien, S., Firtion, G., Anderson, S. T., Hirt, D., Solas, C., Peytavin, G., . . . Tréluyer, J. -M. (2011). Lopinavir/ritonavir population pharmacokinetics in neonates and infants.. British journal of clinical pharmacology, 71(6), 956-960. doi:10.1111/j.1365-2125.2011.03926.xDOI: 10.1111/j.1365-2125.2011.03926.x
Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies (Journal article)
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6), 2775-2782. doi:10.1128/AAC.00887-10DOI: 10.1128/AAC.00887-10
Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies (Journal article)
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. Antimicrobial Agents and Chemotherapy, 55(6), 2775-2782. doi:10.1128/aac.00887-10DOI: 10.1128/aac.00887-10
Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults (Journal article)
Byakika-Kibwika, P., Lamorde, M., Lwabi, P., Nyakoojo, W. B., Okaba-Kayom, V., Mayanja-Kizza, H., . . . Merry, C. (2011). Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults. Chemotherapy Research and Practice, 2011, 1-4. doi:10.1155/2011/393976DOI: 10.1155/2011/393976
Byakika-Kibwika, P., Lamorde, M., Lwabi, P., Nyakoojo, W. B., Okaba-Kayom, V., Mayanja-Kizza, H., . . . Merry, C. (2011). Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults.. Chemotherapy research and practice, 2011, 393976. doi:10.1155/2011/393976DOI: 10.1155/2011/393976
Byakika-Kibwika, P., Lamorde, M., Mayanja-Kizza, H., Khoo, S., Merry, C., & Van Geertruyden, J. -P. (2011). Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.. Malaria research and treatment, 2011, 703730. doi:10.4061/2011/703730DOI: 10.4061/2011/703730
Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology (Poster)
Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. (Journal article)
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2011). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. The Journal of antimicrobial chemotherapy, 66(3), 635-640. doi:10.1093/jac/dkq468DOI: 10.1093/jac/dkq468
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy (Journal article)
Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.xDOI: 10.1111/j.1468-1293.2010.00865.x
Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort (Journal article)
Kigen, G., Kimaiyo, S., Nyandiko, W., Faragher, B., Sang, E., Jakait, B., . . . Khoo, S. H. (2011). Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort. PLOS ONE, 6(2). doi:10.1371/journal.pone.0016800DOI: 10.1371/journal.pone.0016800
Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir (Journal article)
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 879-887. doi:10.1128/AAC.00623-10DOI: 10.1128/AAC.00623-10
Ageing with HIV: medication use and risk for potential drug-drug interactions. (Journal article)
Marzolini, C., Back, D., Weber, R., Furrer, H., Cavassini, M., Calmy, A., . . . Swiss HIV Cohort Study Members. (2011). Ageing with HIV: medication use and risk for potential drug-drug interactions.. The Journal of antimicrobial chemotherapy, 66(9), 2107-2111. doi:10.1093/jac/dkr248DOI: 10.1093/jac/dkr248
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. (Journal article)
Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . for HIV/AIDS, G. C. N. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.. J Antimicrob Chemother, 66(6), 1332-1339.
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin (Journal article)
Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Ryan, M., Coakley, P., Boffito, M., . . . Merry, C. (2011). Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Journal of Antimicrobial Chemotherapy, 66(1), 180-183. doi:10.1093/jac/dkq411DOI: 10.1093/jac/dkq411
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. (Journal article)
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2011). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother, 66(3), 635-640.
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals (Journal article)
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J Acquir Immune Defic Syndr, 58(5), 450-457. doi:10.1097/QAI.0b013e3182364c67DOI: 10.1097/QAI.0b013e3182364c67
Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies. (Journal article)
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.. Antimicrob Agents Chemother, 55(6), 2775-2782.
The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir (Journal article)
Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir. Int J STD AIDS, 22, 11-14.
The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir. (Journal article)
Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir.. Int J STD AIDS, 22, 11-14.
Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir (Journal article)
Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir. International Journal of STD & AIDS, 22(1), 11-14. doi:10.1258/ijsa.2009.009184DOI: 10.1258/ijsa.2009.009184
Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir. (Journal article)
Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.. International journal of STD & AIDS, 22(1), 11-14. doi:10.1258/ijsa.2009.009184DOI: 10.1258/ijsa.2009.009184
2010
Grapefruit-Drug Interactions (Journal article)
Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-Drug Interactions. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000DOI: 10.2165/11585250-000000000-00000
Pharmacokinetic evaluation of etravirine (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine. Expert Opinion on Drug Metabolism & Toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811DOI: 10.1517/17425255.2010.535811
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance (Journal article)
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(12), 5242-5250. doi:10.1128/AAC.00781-10DOI: 10.1128/AAC.00781-10
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance (Journal article)
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/aac.00781-10DOI: 10.1128/aac.00781-10
Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women (Journal article)
Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Flaherty, J. P., Boffito, M., Namakula, R., . . . Scarsi, K. K. (2010). Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(3), 345-350. doi:10.1097/QAI.0b013e3181e9871bDOI: 10.1097/QAI.0b013e3181e9871b
Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults (Journal article)
Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . Khoo, S. (2010). Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults. Antimicrobial Agents and Chemotherapy, 54(7), 2965-2973. doi:10.1128/aac.01198-09DOI: 10.1128/aac.01198-09
Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease (Journal article)
Milburn, H., Ashman, N., Davies, P., Doffman, S., Drobniewski, F., Khoo, S., . . . Snelson, C. (2010). Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax, 65(6), 559-570. doi:10.1136/thx.2009.133173DOI: 10.1136/thx.2009.133173
Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. (Journal article)
British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee., Milburn, H., Ashman, N., Davies, P., Doffman, S., Drobniewski, F., . . . Snelson, C. (2010). Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease.. Thorax, 65(6), 557-570. doi:10.1136/thx.2009.133173DOI: 10.1136/thx.2009.133173
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals (Journal article)
Seden, K., Back, D., & Khoo, S. (2010). New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. Journal of Antimicrobial Chemotherapy, 65(6), 1079-1085. doi:10.1093/jac/dkq086DOI: 10.1093/jac/dkq086
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds (Journal article)
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 878(19), 1455-1465. doi:10.1016/j.jchromb.2010.03.036DOI: 10.1016/j.jchromb.2010.03.036
Recognition of Risk for Clinically Significant Drug Interactions among HIV-Infected Patients Receiving Antiretroviral Therapy (Journal article)
Evans-Jones, J. G., Cottle, L. E., Back, D. J., Gibbons, S., Beeching, N. J., Carey, P. B., & Khoo, S. H. (2010). Recognition of Risk for Clinically Significant Drug Interactions among HIV-Infected Patients Receiving Antiretroviral Therapy. CLINICAL INFECTIOUS DISEASES, 50(10), 1419-1421. doi:10.1086/652149DOI: 10.1086/652149
Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. (Journal article)
Mackie, N. E., Phillips, A. N., Kaye, S., Booth, C., & Geretti, A. -M. (2010). Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.. The Journal of infectious diseases, 201(9), 1303-1307. doi:10.1086/651618DOI: 10.1086/651618
Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes (Journal article)
Janneh, O., Bray, P. G., Jones, E., Wyen, C., Chiba, P., Back, D. J., & Khoo, S. H. (2010). Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. Journal of Antimicrobial Chemotherapy, 65(5), 906-916. doi:10.1093/jac/dkq082DOI: 10.1093/jac/dkq082
Tenofovir disoproxil fumarate and the kidney in HIV-infected patients: the evidence thus far (Journal article)
Mohammed I Danjuma, Atif Mohiuddin, Munir Pirmohamed, Saye K. (2010). Tenofovir disoproxil fumarate and the kidney in HIV-infected patients: the evidence thus far. HIV Therapy, 4(3), 345-359. doi:10.2217/hiv.10.16DOI: 10.2217/hiv.10.16
Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study (Journal article)
Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., Furrer, H., . . . Battegay, M. (2010). Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15(3), 413-423. doi:10.3851/imp1540DOI: 10.3851/imp1540
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. (Journal article)
Seden, K., Back, D., & Khoo, S. (2010). New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.. The Journal of antimicrobial chemotherapy, 65(6), 1079-1085. doi:10.1093/jac/dkq086DOI: 10.1093/jac/dkq086
Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes (Journal article)
Janneh, O., Bray, P. G., Jones, E., Wyen, C., Chiba, P., Back, D. J., & Khoo, S. H. (2010). Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(5), 906-916. doi:10.1093/jac/dkq082DOI: 10.1093/jac/dkq082
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans (Journal article)
Wakeham, K., Parkes-Ratanshi, R., Watson, V., Ggayi, A. -B., Khoo, S., & Lalloo, D. G. (2010). Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(2), 316-319. doi:10.1093/jac/dkp451DOI: 10.1093/jac/dkp451
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms (Journal article)
Hartkoorn, R. C., San Kwan, W., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms. PHARMACOGENETICS AND GENOMICS, 20(2), 112-120. doi:10.1097/FPC.0b013e328335b02dDOI: 10.1097/FPC.0b013e328335b02d
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms (Journal article)
Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics, 20(2), 112-120. doi:10.1097/fpc.0b013e328335b02dDOI: 10.1097/fpc.0b013e328335b02d
Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS (Conference Paper)
Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . Owen, A. (2010). Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 286). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. (Journal article)
Wakeham, K., Parkes-Ratanshi, R., Watson, V., Ggayi, A., Khoo, S., & Lalloo, D. G. (2010). Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.. J Antimicrobial Chemother, 65(2), 316-319.
Factors influencing lopinavir and atazanavir plasma concentration. (Journal article)
Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . UK CHIC Steering Committee. (2010). Factors influencing lopinavir and atazanavir plasma concentration.. The Journal of antimicrobial chemotherapy, 65(1), 129-137. doi:10.1093/jac/dkp408DOI: 10.1093/jac/dkp408
Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens (Conference Paper)
Pushpakom, S., Liptrott, N. J., RodrÃguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 352). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Grapefruit juice drug interactions (Journal article)
Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit juice drug interactions. Drugs, 70(18), 2373-2407.
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. (Journal article)
Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.. Pharmacogenet Genomics, 20(2), 112-120.
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. (Journal article)
Seden, K., Back, D., & Khoo, S. (2010). New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.. J Antimicrob Chemother, 65(6), 1079-1085.
Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3- (Journal article)
Paediatric European Network for Treatment of AIDS PENTA Group au. (2010). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-. Antivir Ther, 15(3), 297-305.
Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.. Antiviral research, 85(1), 176-189.
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. (Journal article)
Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . DART Trial Team. (2010). Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.. Antimicrobial agents and chemotherapy, 54(7), 2965-2973. doi:10.1128/aac.01198-09DOI: 10.1128/aac.01198-09
Pharmacokinetics of lopinavir/ritonavir with and without non-nucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults (Journal article)
Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . on behalf of the DART trial team. (2010). Pharmacokinetics of lopinavir/ritonavir with and without non-nucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. Antimicrob Agents Chemother, 54(7), 2965-2973.
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. (Journal article)
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother..
Population pharmacokinetic modelling of the association between 63396C->T Pregnane X Receptor polymorphism and unboosted atazanavir clearance (Journal article)
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population pharmacokinetic modelling of the association between 63396C->T Pregnane X Receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother, 54(12), 5242-5250.
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. (Journal article)
Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., Furrer, H., . . . Swiss HIV Cohort Study. (2010). Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.. Antiviral therapy, 15(3), 413-423. doi:10.3851/imp1540DOI: 10.3851/imp1540
Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2 (Conference Paper)
Moss, D., Kwan, W., Liptrott, N., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 293). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir (Journal article)
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother, 55(2), 879-887.
Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. (Journal article)
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir.. Antimicrob Agents Chemother, 55(2), 879-887.
Response to planned treatment interruptions in HIV infection varies across childhood. (Journal article)
Paediatric European Network for Treatment of AIDS. Group authors., & Khoo, S. (2010). Response to planned treatment interruptions in HIV infection varies across childhood.. AIDS., 24(2), 231-241.
Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets. (Journal article)
Poerksen, G., Pollock, L., Moons, P., Chesshyre, E., Burger, D., Khoo, S., & Molyneux, E. (2010). Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.. Antiviral therapy, 15(3), 343-350. doi:10.3851/imp1544DOI: 10.3851/imp1544
Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets. (Journal article)
Poerksen, G., Pollock, L., Moons, P., Chesshyre, E., Burger, D., Khoo, S., & Molyneux, E. (2010). Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.. Antivir Ther, 15(2), 343-350.
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. (Journal article)
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.. J Chromatogr B Analyt Technol Biomed Life Sci, 878(19), 1455-1465.
2009
P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir (Journal article)
Janneh, O., Anwar, T., Jungbauer, C., Kopp, S., Khoo, S. H., Back, D. J., & Chiba, P. (2009). P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. ANTIVIRAL THERAPY, 14(7), 965-974. doi:10.3851/IMP1399DOI: 10.3851/IMP1399
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. (Journal article)
Pollock, L., Else, L., Poerksen, G., Molyneux, E., Moons, P., Walker, S., . . . Khoo, S. (2009). Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.. The Journal of antimicrobial chemotherapy, 64(6), 1251-1259. doi:10.1093/jac/dkp358DOI: 10.1093/jac/dkp358
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes (Journal article)
Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother, 64(5), 1002-1007.
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes (Journal article)
Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. H. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 64(5), 1002-1007. doi:10.1093/jac/dkp335DOI: 10.1093/jac/dkp335
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population (Journal article)
Mahungu, T., Smith, C., Turner, F., Egan, D., Youle, M., Johnson, M., . . . Owen, A. (2009). Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med, 10(5), 310-317.
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC (Journal article)
Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 68(3), 375-380. doi:10.1111/j.1365-2125.2009.03462.xDOI: 10.1111/j.1365-2125.2009.03462.x
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC (Journal article)
Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br J Clin Pharmacol, 68(3), 375-380.
The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz (Journal article)
Mahungu, T. W., Nair, D., Smith, C. J., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz. CLINICAL PHARMACOLOGY & THERAPEUTICS, 86(2), 204-211. doi:10.1038/clpt.2009.78DOI: 10.1038/clpt.2009.78
Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. (Journal article)
Seden, K., Back, D., & Khoo, S. (2009). Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable.. The Journal of antimicrobial chemotherapy, 64(1), 5-8. doi:10.1093/jac/dkp152DOI: 10.1093/jac/dkp152
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers (Journal article)
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. Journal of Antimicrobial Chemotherapy, 63(6), 1233-1243. doi:10.1093/jac/dkp102DOI: 10.1093/jac/dkp102
Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study (Journal article)
Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. CLINICAL INFECTIOUS DISEASES, 48(11), E108-E116. doi:10.1086/598507DOI: 10.1086/598507
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers (Journal article)
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 63(6), 1233-1243. doi:10.1093/jac/dkp102DOI: 10.1093/jac/dkp102
Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population (Journal article)
Mahungu, T. W., Smith, C. J., Turner, F., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV MEDICINE, 10(5), 310-317. doi:10.1111/j.1468-1293.2008.00689.xDOI: 10.1111/j.1468-1293.2008.00689.x
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC (Journal article)
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. British Journal of Pharmacology, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.xDOI: 10.1111/j.1476-5381.2008.00050.x
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC (Journal article)
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. BRITISH JOURNAL OF PHARMACOLOGY, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.xDOI: 10.1111/j.1476-5381.2008.00050.x
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2009). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV & AIDS, (in pr.
Drug-Drug Interactions Involving Antiretrovirals (Journal article)
Seden, K., Back, D. J., & Khoo, S. H. (2009). Drug-Drug Interactions Involving Antiretrovirals. Journal of Antimicrobial Chemotherapy, (in pr.
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study (Journal article)
Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis, 48(11), e108-e116.
2008
Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry (Journal article)
Liprott, N. J., Khoo, S. H., Back, D. J., & Owen, A. (2008). Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. JOURNAL OF IMMUNOLOGICAL METHODS, 339(2), 270-274. doi:10.1016/j.jim.2008.09.010DOI: 10.1016/j.jim.2008.09.010
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. (Journal article)
Boffito, M., Else, L., Back, D., Taylor, J., Khoo, S., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.. Antiviral therapy, 13(7), 901-907. doi:10.1177/135965350801300702DOI: 10.1177/135965350801300702
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. (Journal article)
Dickinson, L., Boffito, M., Back, D., Khoo, S., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.. The Journal of antimicrobial chemotherapy, 62(6), 1344-1355.
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals (Journal article)
Dickinson, L., Boffito, M., Back, D. J., Khoo, S. H., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(6), 1344-1355. doi:10.1093/jac/dkn399DOI: 10.1093/jac/dkn399
Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir (Journal article)
Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., . . . Owen, A. (2008). Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir. CLINICAL INFECTIOUS DISEASES, 47(9), 1222-1225. doi:10.1086/592304DOI: 10.1086/592304
Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy? (Journal article)
Winston, A., & Khoo, S. (2008). Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?. Current opinion in HIV and AIDS, 3(6), 608-611. doi:10.1097/coh.0b013e328312972eDOI: 10.1097/coh.0b013e328312972e
Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir (Journal article)
Janneh, O., Hartkoorn, R. C., Jones, E., Owen, A., Ward, S. A., Davey, R., . . . Khoo, S. H. (2008). Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. BRITISH JOURNAL OF PHARMACOLOGY, 155(6), 875-883. doi:10.1038/bjp.2008.320DOI: 10.1038/bjp.2008.320
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. (Journal article)
Moltó, J., Santos, J. R., Pérez-Alvarez, N., Cedeño, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.. Antimicrobial agents and chemotherapy, 52(11), 3928-3932. doi:10.1128/aac.00520-08DOI: 10.1128/aac.00520-08
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. (Journal article)
Byakika-Kibwika, P., Lamorde, M., Kalemeera, F., D'Avolio, A., Mauro, S., Di Perri, G., . . . Merry, C. (2008). Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.. The Journal of antimicrobial chemotherapy, 62(5), 1113-1117. doi:10.1093/jac/dkn290DOI: 10.1093/jac/dkn290
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. (Journal article)
Gazzard, B. G., Anderson, J., Babiker, A., Boffito, M., Brook, G., Brough, G., . . . BHIVA Treatment Guidelines Writing Group. (2008). British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.. HIV medicine, 9(8), 563-608. doi:10.1111/j.1468-1293.2008.00636.xDOI: 10.1111/j.1468-1293.2008.00636.x
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. (Journal article)
Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . UK CHIC Study. (2008). Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.. Antiviral therapy, 13(5), 675-685. doi:10.1177/135965350801300507DOI: 10.1177/135965350801300507
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing (Journal article)
Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (n.d.). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. Journal of Antimicrobial Chemotherapy, 62(1), 161-167. doi:10.1093/jac/dkn187DOI: 10.1093/jac/dkn187
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing (Journal article)
Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (2008). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(1), 161-167. doi:10.1093/jac/dkn187DOI: 10.1093/jac/dkn187
HIV induces deletion of T cell receptor variable gene product-specific T cells. (Journal article)
Bansal, A. S., Green, L. M., Khoo, S. H., Pumphrey, R. S., Haeney, M. R., & Mandal, B. K. (1993). HIV induces deletion of T cell receptor variable gene product-specific T cells.. Clinical and experimental immunology, 94(1), 17-20. doi:10.1111/j.1365-2249.1993.tb05970.xDOI: 10.1111/j.1365-2249.1993.tb05970.x
Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. (Journal article)
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.. Therapeutic drug monitoring, 30(3), 306-313.
Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis (Journal article)
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis. THERAPEUTIC DRUG MONITORING, 30(3), 306-313. doi:10.1097/FTD.0b013e318177209eDOI: 10.1097/FTD.0b013e318177209e
Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis (Journal article)
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis. THERAPEUTIC DRUG MONITORING, 30(3), 306-313.
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. (Journal article)
Cressey, T. R., Green, H., Khoo, S., Treluyer, J. -M., Compagnucci, A., Saidi, Y., . . . Paediatric European Network for Treatment of AIDS II Study Group. (2008). Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 46(10), 1601-1608. doi:10.1086/587657DOI: 10.1086/587657
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2008). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV and AIDS, 3(3), 296-305. doi:10.1097/coh.0b013e3282f82bf1DOI: 10.1097/coh.0b013e3282f82bf1
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2008). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.. Current opinion in HIV and AIDS, 3(3), 296-305. doi:10.1097/coh.0b013e3282f82bf1DOI: 10.1097/coh.0b013e3282f82bf1
Pharmacogenetics of antiretroviral agents (Journal article)
Owen, A., & Khoo, S. H. (2008). Pharmacogenetics of antiretroviral agents. CURRENT OPINION IN HIV AND AIDS, 3(3), 288-295. doi:10.1097/COH.0b013e3282f7cda4DOI: 10.1097/COH.0b013e3282f7cda4
Impact of <i>CYP2B6</i> 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients (Journal article)
Wyen, C., Hendra, H., Vogel, M., Hoffmann, C., Knechten, H., Brockmeyer, N. H., . . . Owen, A. (2008). Impact of <i>CYP2B6</i> 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 61(4), 914-918. doi:10.1093/jac/dkn029DOI: 10.1093/jac/dkn029
Hypoadrenalism is not associated with early mortality during tuberculosis treatment in Malawi. (Journal article)
Beadsworth, M. B. J., van Oosterhout, J. J., Diver, M. J., Faragher, E. B., Shenkin, A., Mwandumba, H. C., . . . Zijlstra, E. E. (2008). Hypoadrenalism is not associated with early mortality during tuberculosis treatment in Malawi.. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 12(3), 314-318.
Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication (Journal article)
Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . Khoo, S. (2008). Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication. Antiviral Therapy, 13(5), 675-685.
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation (Journal article)
Back, D., Else, L., Khoo, S., Boffito, M., Taylor, J., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. ANTIVIRAL THERAPY, 13(7), 901-907.
2007
Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes (Journal article)
Janneh, O., Jones, E., Chandler, B., Owen, A., & Khoo, S. H. (2007). Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(5), 987-993. doi:10.1093/jac/dkm353DOI: 10.1093/jac/dkm353
Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification (Journal article)
Detsika, M. G., Chandler, B., Khoo, S. H., Winstanley, C., Cane, P., Back, D. J., & Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(4), 881-884. doi:10.1093/jac/dkm281DOI: 10.1093/jac/dkm281
A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin (Journal article)
Hartkoorn, R. C., Khoo, S., Back, D. J., Tjia, J. F., Waitt, C. J., Chaponda, M., . . . Ward, S. A. (2007). A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 857(1), 76-82. doi:10.1016/j.jchromb.2007.07.005DOI: 10.1016/j.jchromb.2007.07.005
Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects (Journal article)
Chandler, B., Detsika, M., Khoo, S. H., Williams, J., Back, D. J., & Owen, A. (2007). Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(3), 685-689. doi:10.1093/jac/dkm230DOI: 10.1093/jac/dkm230
Stopping antiretroviral therapy. (Journal article)
Taylor, S., Boffito, M., Khoo, S., Smit, E., & Back, D. (2007). Stopping antiretroviral therapy.. AIDS (London, England), 21(13), 1673-1682. doi:10.1097/qad.0b013e3281c61394DOI: 10.1097/qad.0b013e3281c61394
Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i> (Journal article)
Chandler, B., Detsika, M., Owen, A., Evans, S., Hartkoorn, R. C., Cane, P. A., . . . Khoo, S. H. (2007). Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i>. ANTIVIRAL THERAPY, 12(5), 831-834. Retrieved from https://www.webofscience.com/
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals. (Journal article)
Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367.
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals. (Journal article)
Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367. doi:10.1097/ftd.0b013e3180683b25DOI: 10.1097/ftd.0b013e3180683b25
Combining resistance and pharmacology for optimum patient care (Journal article)
Khoo, S. H., Winston, A., & Back, D. J. (2007). Combining resistance and pharmacology for optimum patient care. CURRENT OPINION IN HIV AND AIDS, 2(3), 157-168. doi:10.1097/COH.0b013e3280f31d27DOI: 10.1097/COH.0b013e3280f31d27
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein (Journal article)
Hartkoorn, R. C., Chandler, B., Owen, A., Ward, S. A., Squire, S. B., Back, D. J., & Khoo, S. H. (2007). Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. TUBERCULOSIS, 87(3), 248-255. doi:10.1016/j.tube.2006.12.001DOI: 10.1016/j.tube.2006.12.001
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. (Journal article)
Kikaire, B., Khoo, S., Walker, A. S., Ssali, F., Munderi, P., Namale, L., . . . DART Trial Team. (2007). Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.. AIDS (London, England), 21(6), 733-737. doi:10.1097/qad.0b013e3280121801DOI: 10.1097/qad.0b013e3280121801
Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?' (Journal article)
Hastings, I. M., Lalloo, D. G., & Khoo, S. H. (2007). Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'. AIDS, 21(2), 258-259. doi:10.1097/QAD.0b013e32801121fbDOI: 10.1097/QAD.0b013e32801121fb
Effect of transporter modulation on the emergence of nelfinavir resistance in vitro (Journal article)
Chandler, B., Detsika, M., Owen, A., Evans, S., Hartkoorn, R. C., Cane, P. A., . . . Khoo, S. H. (2007). Effect of transporter modulation on the emergence of nelfinavir resistance in vitro. Antivir Ther, 12(5), 831-834. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17713167
HIV and pharmacogenomics in 2007. (Journal article)
Khoo, S. (2007). HIV and pharmacogenomics in 2007.. Pharmacogenomics, 8(1), 25-27. doi:10.2217/14622416.8.1.25DOI: 10.2217/14622416.8.1.25
Stopping antiretroviral therapy (Journal article)
Taylor, S., Boffito, M., Khoo, S., Smit, E., & Back, D. (2007). Stopping antiretroviral therapy. AIDS, 21(13), 1673-1682. doi:10.1097/QAD.0b013e3281c61394DOI: 10.1097/QAD.0b013e3281c61394
2006
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. (Journal article)
Friedland, G., Khoo, S., Jack, C., & Lalloo, U. (2006). Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.. The Journal of antimicrobial chemotherapy, 58(6), 1299-1302. doi:10.1093/jac/dkl399DOI: 10.1093/jac/dkl399
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. (Journal article)
Ford, J., Boffito, M., Maitland, D., Hill, A., Back, D., Khoo, S., . . . Pozniak, A. (2006). Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.. The Journal of antimicrobial chemotherapy, 58(5), 1009-1016. doi:10.1093/jac/dkl379DOI: 10.1093/jac/dkl379
No room for complacency on drug resistance in Africa (Journal article)
Hastings, I. M., Lalloo, D. G., & Khoo, S. H. (2006). No room for complacency on drug resistance in Africa. NATURE, 444(7115), 31. doi:10.1038/444031cDOI: 10.1038/444031c
Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug (Journal article)
Hider, S. L., Owen, A., Hartkoorn, R., Khoo, S., Back, D., Silman, A. J., & Bruce, I. N. (2006). Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. ANNALS OF THE RHEUMATIC DISEASES, 65(10), 1390-1393. doi:10.1136/ard.2005.049189DOI: 10.1136/ard.2005.049189
Pharmacogenetics of HIV therapy (Journal article)
Owen, A., Pirmohamed, M., Khoo, S. H., & Back, D. J. (2006). Pharmacogenetics of HIV therapy. PHARMACOGENETICS AND GENOMICS, 16(10), 693-703. doi:10.1097/01.fpc.0000236338.41799.57DOI: 10.1097/01.fpc.0000236338.41799.57
Optimal sampling strategies for early pharmacodynamic measures in tuberculosis (Journal article)
Davies, G. R., Khoo, S. H., & Aarons, L. J. (2006). Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 58(3), 594-600. doi:10.1093/jac/dkl272DOI: 10.1093/jac/dkl272
Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment (Journal article)
Davies, G. R., Brindle, R., Khoo, S. H., & Aarons, L. J. (2006). Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 50(9), 3154-3156. doi:10.1128/AAC.00774-05DOI: 10.1128/AAC.00774-05
Will ART rollout in Africa drive an epidemic of drug resistant HIV? (Journal article)
Hastings, I. M., Lalloo, D., & Khoo, S. H. (2006). Will ART rollout in Africa drive an epidemic of drug resistant HIV?. AIDS, 20(9), 1354-1356. doi:10.1097/01.aids.0000232257.97027.80DOI: 10.1097/01.aids.0000232257.97027.80
An update on therapeutic drug monitoring for antiretroviral drugs. (Journal article)
Back, D., Gibbons, S., & Khoo, S. (2006). An update on therapeutic drug monitoring for antiretroviral drugs.. Therapeutic drug monitoring, 28(3), 468-473. doi:10.1097/01.ftd.0000211825.57984.41DOI: 10.1097/01.ftd.0000211825.57984.41
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response. (Journal article)
Winston, A., Patel, N., Back, D., Khoo, S., Bulbeck, S., Mandalia, S., . . . Boffito, M. (2006). Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.. Journal of acquired immune deficiency syndromes (1999), 41(5), 675-676. doi:10.1097/01.qui.0000209910.27997.d9DOI: 10.1097/01.qui.0000209910.27997.d9
Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - A randomized controlled trial of therapeutic drug monitoring and adherence support (Journal article)
Khoo, S. H., Lloyd, J., Dalton, M., Bonington, A., Hart, E., Gibbons, S., . . . Back, D. J. (2006). Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - A randomized controlled trial of therapeutic drug monitoring and adherence support. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 41(4), 461-467. doi:10.1097/01.qai.0000218345.65434.21DOI: 10.1097/01.qai.0000218345.65434.21
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals (Journal article)
Back, D. J., Owen, A., & Khoo, S. H. (2006). Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. CLINICAL PHARMACOKINETICS, 45(2), 213-214. doi:10.2165/00003088-200645020-00006DOI: 10.2165/00003088-200645020-00006
No room for complacency on drug resistance in Africa (Journal article)
Hastings, I. M., Lalloo, D. G., & Khoo, S. (2006). No room for complacency on drug resistance in Africa. Nature, 444(7115), 31.
Pharmacogenetics of HIV therapy (Journal article)
Owen, A., Pirmohamed, M., Khoo, S. H., & Back, D. J. (2006). Pharmacogenetics of HIV therapy. Pharmacogenet Genomics, 16(10), 693-703. doi:10.1097/01.fpc.0000236338.41799.57DOI: 10.1097/01.fpc.0000236338.41799.57
Pharmacokinetics of reverse transcriptase inhibitors (Chapter)
Hoggard, P., Kewn, S., Khoo, S., & Back, D. (2006). Pharmacokinetics of reverse transcriptase inhibitors. In G. Skowron, & R. Ogden (Eds.), Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (pp. xxx). Totowa, New Jersey: Humana Press.
Pharmacological Optimization of PIs and NNRTIs (POPIN)- a randomised controlled trial of therapeutic drug monitoring and adherence support. (Journal article)
Khoo, S. H., Lloyd, J., Dalton, M., Bonington, A., Hart, E., Gibbons, S., . . . Back, D. J. (2006). Pharmacological Optimization of PIs and NNRTIs (POPIN)- a randomised controlled trial of therapeutic drug monitoring and adherence support.. J Acquir Immune Defic Syndr, 41(4), 461-467.
2005
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. (Journal article)
Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90. doi:10.1016/j.jchromb.2005.09.032DOI: 10.1016/j.jchromb.2005.09.032
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. (Journal article)
Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90.
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. doi:10.1097/01.aids.0000194793.36175.40DOI: 10.1097/01.aids.0000194793.36175.40
Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. (Journal article)
Sadiq, S. T., Fredericks, S., Khoo, S. H., Rice, P., & Holt, D. W. (2005). Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance.. AIDS (London, England), 19(15), 1716-1717. doi:10.1097/01.aids.0000186828.99032.60DOI: 10.1097/01.aids.0000186828.99032.60
Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals (Journal article)
Almond, L. M., Hoggard, P. G., Edirisinghe, D., Khoo, S. H., & Back, D. J. (2005). Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 56(4), 738-744. doi:10.1093/jac/dki308DOI: 10.1093/jac/dki308
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine (Journal article)
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 314(3), 1202-1209. doi:10.1124/jpet.105.086272DOI: 10.1124/jpet.105.086272
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. (Journal article)
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.. The Journal of pharmacology and experimental therapeutics, 314(3), 1202-1209. doi:10.1124/jpet.105.086272DOI: 10.1124/jpet.105.086272
Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). (Journal article)
Bergshoeff, A., Burger, D., Verweij, C., Farrelly, L., Flynn, J., Le Prevost, M., . . . PENTA-13 Study Group. (2005). Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).. Antiviral therapy, 10(2), 239-246. doi:10.1177/135965350501000207DOI: 10.1177/135965350501000207
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals (Journal article)
Almond, L. M., Edirisinghe, D., Dalton, M., Bonington, A., Back, D. J., & Khoo, S. H. (2005). Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. CLINICAL PHARMACOLOGY & THERAPEUTICS, 78(2), 132-142. doi:10.1016/j.clpt.2005.04.004DOI: 10.1016/j.clpt.2005.04.004
The potential for interactions between antimalarial and antiretroviral drugs. (Journal article)
Khoo, S., Back, D., & Winstanley, P. (2005). The potential for interactions between antimalarial and antiretroviral drugs.. AIDS (London, England), 19(10), 995-1005. doi:10.1097/01.aids.0000174445.40379.e0DOI: 10.1097/01.aids.0000174445.40379.e0
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). (Journal article)
Gazzard, B., & BHIVA Writing Committee. (2005). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).. HIV medicine, 6 Suppl 2, 1-61. doi:10.1111/j.1468-1293.2005.0311b.xDOI: 10.1111/j.1468-1293.2005.0311b.x
Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer. (Journal article)
Hider, S. L., Hoggard, P., Khoo, S., Back, D., & Bruce, I. N. (2005). Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer.. Arthritis and rheumatism, 52(2), 670. doi:10.1002/art.20770DOI: 10.1002/art.20770
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine (Journal article)
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J Pharmacol Exp Ther, 314(3), 1202-1209.
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16284458
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.
2004
The intracellular pharmacology of antiretroviral protease inhibitors (Journal article)
Ford, J., Khoo, S. H., & Back, D. J. (2004). The intracellular pharmacology of antiretroviral protease inhibitors. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 54(6), 982-990. doi:10.1093/jac/dkh487DOI: 10.1093/jac/dkh487
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4 (Journal article)
Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D. J., & Khoo, S. H. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. JOURNAL OF VIROLOGY, 78(21), 12022-12029. doi:10.1128/JVI.78.21.12022-12029.2004DOI: 10.1128/JVI.78.21.12022-12029.2004
Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA (Journal article)
Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. ANTIVIRAL THERAPY, 9(5), 819-821. Retrieved from https://www.webofscience.com/
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen (Journal article)
Isaac, A., Taylor, S., Cane, P., Smit, E., Gihbons, S. E., White, D. J., . . . Back, D. J. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 54(2), 498-502. doi:10.1093/jac/dkh357DOI: 10.1093/jac/dkh357
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. (Journal article)
Ford, J., Boffito, M., Wildfire, A., Hill, A., Back, D., Khoo, S., . . . Pozniak, A. (2004). Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.. Antimicrobial agents and chemotherapy, 48(7), 2388-2393. doi:10.1128/aac.48.7.2388-2393.2004DOI: 10.1128/aac.48.7.2388-2393.2004
The relationship between nevirapine plasma concentrations and abnormal liver function tests (Journal article)
Almond, L. M., Boffito, M., Hoggard, P. G., Bonora, S., Raiteri, R., Reynolds, H. E., . . . Di Perri, G. (2004). The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS RESEARCH AND HUMAN RETROVIRUSES, 20(7), 716-722. doi:10.1089/0889222041524670DOI: 10.1089/0889222041524670
A British Second World War veteran with disseminated strongyloidiasis (Journal article)
Gill, G. V., Beeching, N. J., Khoo, S., Bailey, J. W., Partridge, S., Blundell, J. W., & Luksza, A. R. (2004). A British Second World War veteran with disseminated strongyloidiasis. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 98(6), 382-386. doi:10.1016/j.trstmh.2003.11.002DOI: 10.1016/j.trstmh.2003.11.002
Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression (Journal article)
Ford, J., Cornforth, D., Hoggard, P. G., Cuthbertson, Z., Meaden, E. R., Williams, I., . . . Khoo, S. H. (2004). Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. ANTIVIRAL THERAPY, 9(1), 77-84. Retrieved from https://www.webofscience.com/
Lopinavir protein binding in vivo through the 12-hour dosing interval (Journal article)
Boffito, M., Hoggard, P. G., Lindup, W. E., Bonora, S., Sinicco, A., Khoo, S. H., . . . Back, D. J. (2004). Lopinavir protein binding in vivo through the 12-hour dosing interval. THERAPEUTIC DRUG MONITORING, 26(1), 35-39. doi:10.1097/00007691-200402000-00008DOI: 10.1097/00007691-200402000-00008
Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation. (Journal article)
Behzad-Behbahani, A., Klapper, P. E., Vallely, P. J., Cleator, G. M., & Khoo, S. H. (2004). Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation.. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 29(4), 224-229. doi:10.1016/s1386-6532(03)00155-0DOI: 10.1016/s1386-6532(03)00155-0
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4 (Journal article)
Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D., & Khoo, S. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol, 78(21), 12022-12029.
Intracellular pharmacokinetics of antiretroviral agents. (Journal article)
Owen, A., & Khoo, S. H. (2004). Intracellular pharmacokinetics of antiretroviral agents.. Journal of HIV therapy, 9(4), 97-101.
Lopinavir protein binding in vivo through the 12-hour dosing interval (Journal article)
Boffito, M., Hoggard, P. G., Lindup, W. E., Bonora, S., Sinicco, A., Khoo, S. H., . . . Back, D. J. (2004). Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit, 26(1), 35-39. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14749547
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen (Journal article)
Isaac, A., Taylor, S., Cane, P., Smit, E., Gibbons, S., White, D. J., . . . Back, D. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother, 54(2), 498-502.
Pharmacology update: drug-drug interactions and ethnic and sex differences (Chapter)
Back, D. J., Dickinson, L., Canta, F., & Khoo, S. (2004). Pharmacology update: drug-drug interactions and ethnic and sex differences. In HIV/AIDS Annual Update 2004. Clinical Care Options for HIV.
Value of therapeutic drug monitoring in the management of patients with HIV infection undergoing haemodialysis. (Journal article)
Joseph, A. T., & Khoo, S. H. (2004). Value of therapeutic drug monitoring in the management of patients with HIV infection undergoing haemodialysis.. International journal of STD & AIDS, 15(1), 67-68. doi:10.1258/095646204322637335DOI: 10.1258/095646204322637335
2003
Treating Advanced HIV Infection (Journal article)
Boffito, M., Bonora, S., Sinicco, A., Raiteri, R., Milia, M. G., Khoo, S. H., . . . Di Perri, G. (2003). Treating Advanced HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 34(3), 344-345. doi:10.1097/00126334-200311010-00014DOI: 10.1097/00126334-200311010-00014
Treating advanced HIV infection (Journal article)
Boffito, M., Bonora, S., Sinicco, A., Raiteri, R., Milia, M. G., Khoo, S. H., . . . Di Perri, G. (2003). Treating advanced HIV infection. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 34(3), 344-345. doi:10.1097/00126334-200311010-00014DOI: 10.1097/00126334-200311010-00014
Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines (Journal article)
Owen, A., Hartkoorn, R. C., Khoo, S., & Back, D. (2003). Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines. AIDS, 17(15), 2276-2278. doi:10.1097/00002030-200310170-00024DOI: 10.1097/00002030-200310170-00024
Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes (Journal article)
Janneh, O., Haggard, P., Tjia, J. F., Jones, S. P., Khoo, S. H., Maher, B., . . . Pirmohamed, M. (2003). Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. ANTIVIRAL THERAPY, 8(5), 417-426. Retrieved from https://www.webofscience.com/
Ketoconazole and lopinavir/ritonavir coadministration: Boosting beyond boosting (Journal article)
Boffito, M., Bonora, S., Sales, P., Dal Conte, I., Sinicco, A., Hoggard, P. G., . . . Di Perri, G. (2003). Ketoconazole and lopinavir/ritonavir coadministration: Boosting beyond boosting. AIDS RESEARCH AND HUMAN RETROVIRUSES, 19(10), 941-942. doi:10.1089/088922203322493148DOI: 10.1089/088922203322493148
Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression (Journal article)
Ford, J., Meaden, E. R., Hoggard, P. G., Dalton, M., Newton, P., Williams, I., . . . Back, D. J. (2003). Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 52(3), 354-358. doi:10.1093/jac/dkg381DOI: 10.1093/jac/dkg381
Pharmacokinetic drug interactions with nevirapine. (Journal article)
Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic drug interactions with nevirapine.. Journal of acquired immune deficiency syndromes (1999), 34 Suppl 1, S8-14. doi:10.1097/00126334-200309011-00003DOI: 10.1097/00126334-200309011-00003
The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro (Journal article)
Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S., & Back, D. (2003). The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 33(5), 551-556. doi:10.1097/00126334-200308150-00001DOI: 10.1097/00126334-200308150-00001
Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics. (Journal article)
Hennessy, M., Clarke, S., Spiers, J. P., Mulcahy, F., Kelleher, D., Meadon, E., . . . Barry, M. (2003). Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.. Antiviral therapy, 8(3), 191-198.
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring (Journal article)
Boffito, M., Back, D. J., Hoggard, P. G., Caci, A., Bonora, S., Raiteri, R., . . . Di Perri, G. (2003). Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. AIDS, 17(7), 1107-1108. doi:10.1097/00002030-200305020-00029DOI: 10.1097/00002030-200305020-00029
The role of clinical pharmacology in optimizing antiretroviral therapy (Journal article)
Back, D. J., & Khoo, S. H. (2003). The role of clinical pharmacology in optimizing antiretroviral therapy. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 55(5), 473-476. doi:10.1046/j.1365-2125.2003.01843.xDOI: 10.1046/j.1365-2125.2003.01843.x
A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets (Journal article)
Ford, J., Hoggard, P. G., Owen, A., Khoo, S. H., & Back, D. J. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. JOURNAL OF IMMUNOLOGICAL METHODS, 274(1-2), 129-137. doi:10.1016/S0022-1759(02)00509-4DOI: 10.1016/S0022-1759(02)00509-4
Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells (Journal article)
Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells. JOURNAL OF INFECTIOUS DISEASES, 187(5), 874-875. doi:10.1086/367902DOI: 10.1086/367902
A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets (Journal article)
Ford, J., Hoggard, P. G., & et, A. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J Immunol Methods, 274(1-2), 129-137. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12609539
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. (Journal article)
Pozniak, A., Gazzard, B., Anderson, J., Babiker, A., Churchill, D., Collins, S., . . . BHIVA Writing Committee BHIVA Executive Committee. (2003). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.. HIV medicine, 4 Suppl 1, 1-41.
Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells (Journal article)
Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells. J Infect Dis, 187(5). doi:10.1086/367902DOI: 10.1086/367902
Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients (Journal article)
Kewn, S., Wang, L. H., Hoggard, P. G., Rousseau, F., Hart, R., MacNeela, J. P., . . . Back, D. J. (2003). Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 47(1), 255-261. doi:10.1128/AAC.47.1.255-261.2003DOI: 10.1128/AAC.47.1.255-261.2003
Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes (Journal article)
Janneh, O., Hoggard, P. G., Tjia, J. F., Jones, S. P., Khoo, S. H., Maher, B., . . . Pirmohamed, M. (2003). Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther, 8(5), 417-426. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14640389
Pharmacokinetic drug interactions with nevirapine (Journal article)
Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr, 34 Sup, S8-S14. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14562853
The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro (Journal article)
Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S., & Back, D. (2003). The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr, 33(5), 551-556. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12902797
The role of clinical pharmacology in optimizing antiretroviral therapy (Journal article)
Back, D. J., & Khoo, S. H. (2003). The role of clinical pharmacology in optimizing antiretroviral therapy. Br J Clin Pharmacol, 55(5), 473-476. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12755810
Therapeutic drug monitoring: help or hype? (Conference Paper)
Khoo, S. H. (2003). Therapeutic drug monitoring: help or hype?. In The strategic use of resistance data. Proceedings of the Six HIV Reistance Workshop. London: Mediscript.
2002
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea (Journal article)
Hoggard, P. G., Kewn, S., Maherbe, A., Wood, R., Almond, L. M., Sales, S. D., . . . Khoo, S. H. (2002). Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS, 16(18), 2439-2446. doi:10.1097/00002030-200212060-00009DOI: 10.1097/00002030-200212060-00009
Intracellular accumulation of human immunodeficiency virus protease inhibitors (Journal article)
Khoo, S. H., Hoggard, P. G., Williams, I., Meaden, E. R., Newton, P., Wilkins, E. G., . . . Back, D. J. (2002). Intracellular accumulation of human immunodeficiency virus protease inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46(10), 3228-3235. doi:10.1128/AAC.46.10.3228-3235.2002DOI: 10.1128/AAC.46.10.3228-3235.2002
P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals (Journal article)
Meaden, E. R., Hoggard, P. G., Newton, P., Tjia, J. F., Aldam, D., Cornforth, D., . . . Khoo, S. H. (2002). P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 50(4), 583-588. doi:10.1093/jac/dkf161DOI: 10.1093/jac/dkf161
Therapeutic drug monitoring. (Journal article)
Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic drug monitoring.. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 1(3), 84-85. doi:10.1177/154510970200100301DOI: 10.1177/154510970200100301
Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo (Journal article)
Meaden, E. R., Hoggard, P. G., Khoo, S. H., & Back, D. J. (2002). Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. JOURNAL OF IMMUNOLOGICAL METHODS, 262(1-2), 159-165. doi:10.1016/S0022-1759(02)00020-0DOI: 10.1016/S0022-1759(02)00020-0
Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients (Journal article)
Kewn, S., Hoggard, P. G., Sales, S. D., Jones, K., Maher, B., Khoo, S. H., & Back, D. J. (2002). Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46(1), 135-143. doi:10.1128/AAC.46.1.135-143.2002DOI: 10.1128/AAC.46.1.135-143.2002
Intracellular accumulation of human immunodeficiency virus protease inhibitors (Journal article)
Khoo, S., Hoggard, P. G., Williams, I., Meaden, E. R., Newton, P., Wilkins, E. G., . . . Back, D. (2002). Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother, 46(10), 3228-3235.
Pharmacology (Chapter)
Khoo, S., Back, D. J., & Merry, C. (2002). Pharmacology. In C. A. B. Boucher, & G. Galasso (Eds.), Practical guidelines in antiviral therapy (pp. vii, 344 p.). Amsterdam ; London: Elsevier.
Therapeutic drug monitoring (Journal article)
Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic drug monitoring. J Int Assoc Physicians AIDS Care (Chic), 1(3), 84-85.
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea (Journal article)
Hoggard, P. G., Kewn, S., Maherbe, A., Wood, R., Almond, L. M., Sales, S. D., . . . Khoo, S. H. (2002). Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS, 16(18), 2439-2446. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12461418
2001
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. (Journal article)
BHIVA Writing Committee., & BHIVA Executive Committee. (2001). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.. HIV medicine, 2(4), 276-313. doi:10.1046/j.1464-2662.2001.00083.xDOI: 10.1046/j.1464-2662.2001.00083.x
Therapeutic drug monitoring as a tool in treating HIV infection (Journal article)
Khoo, S. H., Gibbons, S. E., & Back, D. J. (2001). Therapeutic drug monitoring as a tool in treating HIV infection. AIDS, 15, S171-S181. doi:10.1097/00002030-200100005-00021DOI: 10.1097/00002030-200100005-00021
Zidovudine phosphorylation and mitochondrial toxicity <i>in vitro</i> (Journal article)
Sales, S. D., Hoggard, P. G., Sunderland, D., Khoo, S., Hart, C. A., & Back, D. J. (2001). Zidovudine phosphorylation and mitochondrial toxicity <i>in vitro</i>. TOXICOLOGY AND APPLIED PHARMACOLOGY, 177(1), 54-58. doi:10.1006/taap.2001.9288DOI: 10.1006/taap.2001.9288
Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients (Journal article)
Meaden, E. R., Hoggard, P. G., Maher, B., Khoo, S. H., & Back, D. J. (2001). Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS RESEARCH AND HUMAN RETROVIRUSES, 17(14), 1329-1332. doi:10.1089/08892220152596588DOI: 10.1089/08892220152596588
The role of therapeutic drug monitoring in treatment of HIV infection (Journal article)
Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 52, 89S-96S. Retrieved from https://www.webofscience.com/
P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? (Journal article)
Jones, K., Bray, P. G., Khoo, S. H., Davey, R. A., Meaden, E. R., Ward, S. A., & Back, D. J. (2001). P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?. AIDS, 15(11), 1353-1358. doi:10.1097/00002030-200107270-00004DOI: 10.1097/00002030-200107270-00004
The role of therapeutic drug monitoring in treatment of HIV infection (Journal article)
Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(4), 301-308. doi:10.1046/j.1365-2125.2001.01380.xDOI: 10.1046/j.1365-2125.2001.01380.x
Novel IFN-alpha receptor promoter polymorphisms. (Journal article)
Muldoon, J., Uriel, A., Khoo, S., Ollier, W. E., & Hajeer, A. H. (2001). Novel IFN-alpha receptor promoter polymorphisms.. Genes and immunity, 2(3), 159-160. doi:10.1038/sj.gene.6363757DOI: 10.1038/sj.gene.6363757
Differences in the intracellular accumulation of HIV protease inhibitors <i>in vitro</i> and the effect of active transport (Journal article)
Jones, K., Hoggard, P. G., Sales, S. D., Khoo, S., Davey, R., & Back, D. J. (2001). Differences in the intracellular accumulation of HIV protease inhibitors <i>in vitro</i> and the effect of active transport. AIDS, 15(6), 675-681. doi:10.1097/00002030-200104130-00002DOI: 10.1097/00002030-200104130-00002
Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents (Journal article)
Hoggard, P. G., Lloyd, J., Khoo, S. H., Barry, M. G., Dann, L., Gibbons, S. E., . . . Back, D. J. (2001). Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 45(3), 976-980. doi:10.1128/AAC.35.3.976-980.2001DOI: 10.1128/AAC.35.3.976-980.2001
Effect of α<sub>1</sub>-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir <i>in vitro</i> (Journal article)
Jones, K., Hoggard, P. G., Khoo, S., Maher, B., & Back, D. J. (2001). Effect of α<sub>1</sub>-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir <i>in vitro</i>. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(1), 99-102. doi:10.1046/j.1365-2125.2001.01324.xDOI: 10.1046/j.1365-2125.2001.01324.x
Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo (Journal article)
Hoggard, P. G., Sales, S. D., Phiboonbanakit, D., Lloyd, J., Maher, B. A., Khoo, S. H., . . . Back, D. J. (2001). Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 45(2), 577-582. doi:10.1128/AAC.45.2.577-582.2001DOI: 10.1128/AAC.45.2.577-582.2001
The role of therapeutic drug monitoring in treatment of HIV infection. (Journal article)
Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection.. British journal of clinical pharmacology, 52 Suppl 1, 89S-96S. doi:10.1046/j.1365-2125.2001.0520s1089.xDOI: 10.1046/j.1365-2125.2001.0520s1089.x
Therapeutic drug monitoring as a tool in treating HIV infection (Journal article)
Khoo, S. H., Gibbons, S. E., & Back, D. J. (2001). Therapeutic drug monitoring as a tool in treating HIV infection. AIDS, 15 Sup, S171-S181. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11816166
Therapeutic drug monitoring of anti-HIV drugs (Journal article)
Back, D. J., Khoo, S. H., Gibbons, S. E., Reynolds, H., Tjia, J. F., & Merry, C. (2001). Therapeutic drug monitoring of anti-HIV drugs. OPTIMAL DOSE IDENTIFICATION, 1220, 145-160. doi:10.1016/S0531-5131(01)00294-1DOI: 10.1016/S0531-5131(01)00294-1
2000
Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers (Journal article)
Wattanagoon, Y., Bangchang, K. N., Hoggard, P. G., Khoo, S. H., Gibbons, S. E., Phiboonbhanakit, D., . . . Back, D. J. (2000). Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 44(7), 1986-1989. doi:10.1128/AAC.44.7.1986-1989.2000DOI: 10.1128/AAC.44.7.1986-1989.2000
Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection (Journal article)
Back, D. J., Khoo, S. H., Gibbons, S. E., Barry, M. G., & Merry, C. (2000). Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. THERAPEUTIC DRUG MONITORING, 22(1), 122-126. doi:10.1097/00007691-200002000-00026DOI: 10.1097/00007691-200002000-00026
Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression <i>in vitro</i> (Journal article)
Hoggard, P. G., Sales, S. D., Kewn, S., Sunderland, D., Khoo, S. H., Hart, C. A., & Back, D. J. (2000). Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression <i>in vitro</i>. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 11(6), 353-358. doi:10.1177/095632020001100601DOI: 10.1177/095632020001100601
Current uses and future hopes for clinical pharmacology in the management of HIV infection (Journal article)
Back, D., Khoo, S., Maher, B., & Gibbons, S. (2000). Current uses and future hopes for clinical pharmacology in the management of HIV infection. HIV Med, 1 Supp, 12-17. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11737367
Current uses and future hopes for clinical pharmacology in the management of HIV infection. (Journal article)
Back, D., Khoo, S., Maher, B., & Gibbons, S. (2000). Current uses and future hopes for clinical pharmacology in the management of HIV infection.. HIV medicine, 1 Suppl 2, 12-17. doi:10.1046/j.1468-1293.2000.00001.xDOI: 10.1046/j.1468-1293.2000.00001.x
Impaired humoral responses to subgenus D adenovirusenovirus infections in HIV-positive patients. (Journal article)
Lord, A., Bailey, A. S., Klapper, P. E., Snowden, N., & Khoo, S. H. (2000). Impaired humoral responses to subgenus D adenovirusenovirus infections in HIV-positive patients.. Journal of medical virology, 62(4), 405-409. doi:3.0.co;2-8">10.1002/1096-9071(200012)62:4<405::aid-jmv2>3.0.co;2-8DOI: 10.1002/1096-9071(200012)62:4<405::aid-jmv2>3.0.co;2-8
Management of HIV infection in adults (Journal article)
Khoo, S. H., & Wilkins, E. G. L. (2000). Management of HIV infection in adults. Prescribers' Journal, 40(1), 10-19.
1999
The management of Pneumocystis carinii pneumonia. (Journal article)
Vilar, F. J., Khoo, S. H., & Walley, T. (1999). The management of Pneumocystis carinii pneumonia.. British journal of clinical pharmacology, 47(6), 605-609. doi:10.1046/j.1365-2125.1999.00966.xDOI: 10.1046/j.1365-2125.1999.00966.x
Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. (Journal article)
De Jong, J. C., Wermenbol, A. G., Verweij-Uijterwaal, M. W., Slaterus, K. W., Wertheim-Van Dillen, P., Van Doornum, G. J., . . . Hierholzer, J. C. (1999). Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively.. Journal of clinical microbiology, 37(12), 3940-3945. doi:10.1128/jcm.37.12.3940-3945.1999DOI: 10.1128/jcm.37.12.3940-3945.1999
1998
Influenza-like episodes in HIV-positive patients: the role of viral and 'atypical' infections. (Journal article)
Khoo, S. H., Hajia, M., Storey, C. C., Klapper, P. E., Wilkins, E. G., Denning, D. W., . . . Mandal, B. K. (1998). Influenza-like episodes in HIV-positive patients: the role of viral and 'atypical' infections.. AIDS (London, England), 12(7), 751-757.
1997
In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy (Journal article)
Veal, G. J., Barry, M. G., Khoo, S. H., & Back, D. J. (1997). In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 13(6), 481-484. doi:10.1089/aid.1997.13.481DOI: 10.1089/aid.1997.13.481
The integrin-triggered rescue of T lymphocyte apoptosis is blocked in HIV-1-infected individuals. (Journal article)
Ng, T. T., Kanner, S. B., Humphries, M. J., Wickremasinghe, R. G., Nye, K. E., Anderson, J., . . . Morrow, W. J. (1997). The integrin-triggered rescue of T lymphocyte apoptosis is blocked in HIV-1-infected individuals.. Journal of immunology (Baltimore, Md. : 1950), 158(6), 2984-2999.
Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. (Journal article)
Khoo, S. H., Pepper, L., Snowden, N., Hajeer, A. H., Vallely, P., Wilkins, E. G., . . . Ollier, W. E. (1997). Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression.. AIDS (London, England), 11(4), 423-428. doi:10.1097/00002030-199704000-00004DOI: 10.1097/00002030-199704000-00004
Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro (Journal article)
Hoggard, P. G., Kewn, S., Barry, M. G., Khoo, S. H., & Back, D. J. (1997). Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 41(6), 1231-1236. doi:10.1128/AAC.41.6.1231DOI: 10.1128/AAC.41.6.1231
1996
Intracellular metabolism of zidovudine and stavudine in combination. (Journal article)
Hoggard, P., Khoo, S., Barry, M., & Back, D. (1996). Intracellular metabolism of zidovudine and stavudine in combination.. The Journal of infectious diseases, 174(3), 671-672. doi:10.1093/infdis/174.3.671DOI: 10.1093/infdis/174.3.671
Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts. (Journal article)
Khoo, S. H., Wilkins, E. G., Fraser, I. S., Hamour, A. A., & Stanford, J. L. (1996). Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts.. Thorax, 51(9), 932-935. doi:10.1136/thx.51.9.932DOI: 10.1136/thx.51.9.932
Induction of adrenal suppression by megestrol acetate. (Journal article)
Stoffer, S. S., & Krakauer, J. C. (1996). Induction of adrenal suppression by megestrol acetate.. Annals of internal medicine, 124(6), 613-614. doi:10.7326/0003-4819-124-6-199603150-00018DOI: 10.7326/0003-4819-124-6-199603150-00018
Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation (Journal article)
Veal, G. J., Hoggard, P. G., Barry, M. G., Khoo, S., & Back, D. J. (1996). Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. AIDS, 10(5), 546-548. doi:10.1097/00002030-199605000-00016DOI: 10.1097/00002030-199605000-00016
Intracellular glutathione in the peripheral blood cells of HIV-infected patients: Failure to show a deficiency (Journal article)
Pirmohamed, M., Williams, D., Tingle, M. D., Barry, M., Khoo, S. H., OMahony, C., . . . Park, B. K. (1996). Intracellular glutathione in the peripheral blood cells of HIV-infected patients: Failure to show a deficiency. AIDS, 10(5), 501-507. doi:10.1097/00002030-199605000-00008DOI: 10.1097/00002030-199605000-00008
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites (Journal article)
Barry, M. G., Khoo, S. H., Veal, G. J., Hoggard, P. G., Gibbons, S. E., Wilkins, E. G., . . . Back, D. J. (1996). The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS, 10(12), 1361-1367. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8902065
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites (Journal article)
Barry, M. G., Khoo, S. H., Veal, G. J., Hoggard, P. G., Gibbons, S. E., Wilkins, E. G. L., . . . Back, D. J. (1996). The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS, 10(12), 1361-1367. doi:10.1097/00002030-199610000-00008DOI: 10.1097/00002030-199610000-00008
1995
Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology. (Journal article)
Khoo, S. H., Bailey, A. S., de Jong, J. C., & Mandal, B. K. (1995). Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology.. The Journal of infectious diseases, 172(3), 629-637. doi:10.1093/infdis/172.3.629DOI: 10.1093/infdis/172.3.629
MARKED VARIATION IN PYRIMETHAMINE DISPOSITION IN AIDS PATIENTS TREATED FOR CEREBRAL TOXOPLASMOSIS (Journal article)
WINSTANLEY, P., KHOO, S., SZWANDT, S., EDWARDS, G., WILKINS, E., TIJA, J., . . . BRECKENRIDGE, A. (1995). MARKED VARIATION IN PYRIMETHAMINE DISPOSITION IN AIDS PATIENTS TREATED FOR CEREBRAL TOXOPLASMOSIS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 36(2), 435-439. doi:10.1093/jac/36.2.435DOI: 10.1093/jac/36.2.435
Safety and efficacy of combined meningococcal and typhoid vaccine. (Journal article)
Khoo, S. H., St Clair Roberts, J., & Mandal, B. K. (1995). Safety and efficacy of combined meningococcal and typhoid vaccine.. BMJ (Clinical research ed.), 310(6984), 908-909. doi:10.1136/bmj.310.6984.908DOI: 10.1136/bmj.310.6984.908
Controversies in anti-retroviral therapy of adults. (Journal article)
Khoo, S. H., & Wilkins, E. G. (1995). Controversies in anti-retroviral therapy of adults.. The Journal of antimicrobial chemotherapy, 35(2), 245-262. doi:10.1093/jac/35.2.245DOI: 10.1093/jac/35.2.245
Cure of chronic invasive sinus aspergillosis with oral saperconazole. (Journal article)
Khoo, S. H., & Denning, D. W. (1995). Cure of chronic invasive sinus aspergillosis with oral saperconazole.. Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology, 33(1), 63-66. doi:10.1080/02681219580000131DOI: 10.1080/02681219580000131
Prevalence of cortisol deficiency in late HIV disease. (Journal article)
Abbott, M., Khoo, S. H., Hammer, M. R., & Wilkins, E. G. (1995). Prevalence of cortisol deficiency in late HIV disease.. The Journal of infection, 31(1), 1-4. doi:10.1016/s0163-4453(95)91116-2DOI: 10.1016/s0163-4453(95)91116-2
1994
Invasive aspergillosis in patients with AIDS. (Journal article)
Khoo, S. H., & Denning, D. W. (1994). Invasive aspergillosis in patients with AIDS.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 19 Suppl 1, S41-S48. doi:10.1093/clinids/19.supplement_1.s41DOI: 10.1093/clinids/19.supplement_1.s41
Administering amphotericin B--a practical approach. (Journal article)
Khoo, S. H., Bond, J., & Denning, D. W. (1994). Administering amphotericin B--a practical approach.. The Journal of antimicrobial chemotherapy, 33(2), 203-213. doi:10.1093/jac/33.2.203DOI: 10.1093/jac/33.2.203
1993
Serum measurements of soluble CD23 in HIV infection. (Journal article)
Bansal, A. S., Pumphrey, R. S., Mandal, B. K., Khoo, S. H., & Wilson, P. B. (1993). Serum measurements of soluble CD23 in HIV infection.. Immunology, 80(4), 652-653.
1992
Time to finish with "AIDS"? (Journal article)
Khoo, S. H., Bailey, G., Wilkins, E. G., & Denning, D. W. (1992). Time to finish with "AIDS"?. Lancet (London, England), 339(8804), 1298. doi:10.1016/0140-6736(92)91628-lDOI: 10.1016/0140-6736(92)91628-l
Fulminant community acquired infections admitted to an intensive care unit (Journal article)
Khoo, S. H., Creagh-Barry, P., Wilkins, E. G., & Pasvol, G. (1992). Fulminant community acquired infections admitted to an intensive care unit. Q J Med, 83(301), 381-388. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1438673
Fulminant community acquired infections admitted to an intensive care unit. (Journal article)
Khoo, S. H., Creagh-Barry, P., Wilkins, E. G., & Pasvol, G. (1992). Fulminant community acquired infections admitted to an intensive care unit.. The Quarterly journal of medicine, 83(301), 381-388.
Reactivation of tuberculous lymphadenitis during pregnancy. (Journal article)
Warner, T. T., Khoo, S. H., & Wilkins, E. G. (1992). Reactivation of tuberculous lymphadenitis during pregnancy.. The Journal of infection, 24(2), 181-184. doi:10.1016/0163-4453(92)92928-cDOI: 10.1016/0163-4453(92)92928-c
1991
Tuberculous pericarditis confirmed by DNA amplification. (Journal article)
Godfrey-Faussett, P., Wilkins, E. G., Khoo, S., & Stoker, N. (1991). Tuberculous pericarditis confirmed by DNA amplification.. Lancet (London, England), 337(8734), 176-177. doi:10.1016/0140-6736(91)90840-lDOI: 10.1016/0140-6736(91)90840-l
Multiple episodes of bacterial endocarditis occurring over 9 years. (Journal article)
Khoo, S. H., & Larson, H. E. (1991). Multiple episodes of bacterial endocarditis occurring over 9 years.. The Journal of infection, 22(3), 263-268. doi:10.1016/s0163-4453(05)80009-xDOI: 10.1016/s0163-4453(05)80009-x
Northwick Park Infection Consultation Service. Part I. The aims and operation of the service and the general distribution of infection identified by the service between September 1987 and July 1990 [see comment]. (Journal article)
Wilkins, E. G., Hickey, M. M., Khoo, S., Hale, A. D., Umasankar, S., Thomas, P., . . . Larson, E. (1991). Northwick Park Infection Consultation Service. Part I. The aims and operation of the service and the general distribution of infection identified by the service between September 1987 and July 1990 [see comment].. The Journal of infection, 23(1), 47-56. doi:10.1016/0163-4453(91)94041-hDOI: 10.1016/0163-4453(91)94041-h
Northwick Park Infection Consultation Service. Part II. Contribution of the service to patient management: an analysis of results between September 1987 and July 1990. (Journal article)
Wilkins, E. G., Hickey, M. M., Khoo, S., Hale, A. D., Umasankar, S., Thomas, P., . . . Larson, E. (1991). Northwick Park Infection Consultation Service. Part II. Contribution of the service to patient management: an analysis of results between September 1987 and July 1990.. The Journal of infection, 23(1), 57-63. doi:10.1016/0163-4453(91)94063-pDOI: 10.1016/0163-4453(91)94063-p
Severe Helicobacter pylori infection in a patient with AIDS. (Journal article)
Khoo, S. H., & Blackwell, N. (1991). Severe Helicobacter pylori infection in a patient with AIDS.. AIDS (London, England), 5(10), 1253-1255. doi:10.1097/00002030-199110000-00016DOI: 10.1097/00002030-199110000-00016
Severe hyponatraemia in malaria. (Journal article)
Khoo, S. H., & Wilkins, E. G. (1991). Severe hyponatraemia in malaria.. The Journal of infection, 23(1), 85-87. doi:10.1016/0163-4453(91)94195-pDOI: 10.1016/0163-4453(91)94195-p
Undated
Heseltine, T., Hughes, E., Mathew, J., Murray, S. W., Ortega-Martorell, S., Olier, I., . . . Khoo, S. (n.d.). The Relation of Epicardial Adipose Tissue and Cardiovascular Disease in HIV-Positive and HIV-Negative Patients: The Liverpool HIV-Heart Project.
